

SI SUBSTITUTE FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER
06501-081001

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If Known, see 37 CFR 1.5)
09/831846

INTERNATIONAL APPLICATION NO.
PCT/JP99/06449

INTERNATIONAL FILING DATE
18 November 1999

PRIORITY DATE CLAIMED
20 November 1998

TITLE OF INVENTION
NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

APPLICANT(S) FOR DO/EO/US
Shin-ichi Funahashi, Shoji Miyata, Nobuo Nomura, Takahiro Nagase and Osamu Ohara


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other documents or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 - A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:

-
-
-
-
-

CERTIFICATE OF MAILING BY EXPRESS MAIL		Express Mail Label No. EL228026564US
I hereby certify under 37 CFR § 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D C 20231.		
May 15, 2001		Josh Cronin
Date of Deposit	Signature	Typed Name of Person Signing

RECEIVED
 U.S. PATENT AND TRADEMARK OFFICE
 MAY 15 2001

J.S. APPLICATION NO. OF KNOWLEDGE
097/831846

INTERNATIONAL APPLICATION NO.
 PCT/JP99/06449

ATTORNEY'S DOCKET NUMBER
 06501-081001

17. The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)- (5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... **\$1000**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... **\$710**

International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... **\$690**

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... **\$100**

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of **\$130** for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$0.00

Claims	Number Filed	Number Extra	Rate
Total Claims	9 - 20 =	0	x \$18
Independent Claims	2 - 3 =	0	x \$80
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270

\$0.00

\$0.00

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$860.00

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$0.00

SUBTOTAL =

\$860.00

Processing fee of **\$130** for furnishing the English Translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f))

\$0.00

TOTAL NATIONAL FEE =

\$860.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$0.00

TOTAL FEES ENCLOSED =

\$860.00

Amount to be refunded: \$

Charged: \$


- a. A check in the amount of \$860.00 to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Janis K. Fraser, Ph.D., J.D.
 FISH & RICHARDSON P.C.
 225 Franklin Street
 Boston, MA 02110-2804
 (617) 542-5070 phone
 (617) 542-8906 facsimile

SIGNATURE:



NAME

Janis K. Fraser, Ph.D., J.D.

REGISTRATION NUMBER

34,819

09/831846

Attorney's Docket No.: 06501-081001 / C2-010PCT-US

JC18 Rec'd PCT/PTO 1 5 MAY 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shin-ichi Funahashi et al. Art Unit : Unknown
Serial No. : Examiner : Unknown
Filed : Herewith
Title : NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

Box PCT

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the claims:

Amend claims 3, 5, 7 and 8 as follows:

-- 3. A transformant carrying the DNA according to claim 1.

5. A method for producing a protein, said method comprising the steps of culturing the transformant according to claim 3 and recovering the expressed protein from said transformant or the culture supernatant thereof.


7. A method of screening for a compound which binds to a protein, said method comprising the steps of:

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL228026564US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit May 15, 2001

Signature 

Typed or Printed Name of Person Signing Certificate Joshua Cronin

09/831846

Applicant : Shin-ichi Funahashi et al.
Serial No. :
Filed : Herewith
Page : 3

Attorney's Docket No.: 06501-081001

REMARKS


Claims 1-9 are pending, claims 3, 5, 7 and 8 having been amended to delete multiple dependencies. No new matter has been added.

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

May 15, 2001



Ianis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20262044.doc

20262044.doc

Version with markings to show changes made

In the claims:

Claims 3, 5, 7 and 8 have been amended as follows:

3. A transformant carrying the DNA according to claim 1 [or the vector according to claim 2].

5. A method for producing [the] a protein [according to claim 4], said method comprising the steps of culturing the transformant according to claim 3 and recovering the expressed protein from said transformant or the culture supernatant thereof.

7. A method of screening for a compound which binds to [the] a protein [according to claim 4], said method comprising the steps of:

(a) bringing the protein according to claim 4 into contact with a sample to be tested, and

(b) selecting a compound having the activity to bind to the protein [according to claim 4].

8. A method for detecting or measuring [the] a protein [according to claim 4], said method comprising bringing the antibody according to claim 6 into contact with a test sample [that apparently contains the protein according to claim 4], and detecting or measuring the formation of an immune complex of said antibody and [said] a protein that specifically binds said antibody.

3/PRTS

DESCRIPTION

NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

5 Technical Field

The present invention relates to a novel membrane protein specifically expressed in the brain, a nucleic acid molecule encoding the protein, and methods of preparing and using same.

10 Background Art

A variety of cells present in the nerve system form a nerve network that supports high-level brain functions. Elucidation of mechanisms of differentiation, development and apoptosis of the nerve system is an important research subject, to deepen our understanding of functions of nerve system or critical mechanisms of nerve-related disorders. Thus, researches in this field have been energetically pursued.

Recently, a number of novel signal transducer molecules, including the PDZ protein, have been discovered one after another, as indicated by reports on the complex formation of receptors or ion channel molecules with the PDZ proteins such as PSD95/SAP90 in the post-synapse density (PSD) of postsynaptic membrane to perform the signal transduction (Science 269, 1737-1740 (1995), Nature 378, 85-88 (1995), Neuron 17, 103-113 (1996), Neuron 17, 255-265 (1996), J. Neurosci. 16, 2157-2163 (1996), Nature 386, 223, 239 (1997), TIBS 21, 455-458 (1996), J. Yanagisawa et al. (1997) J. Biol. Chem. 272, 7167-7172).

PDZ proteins are thought to serve as modular proteins in the formation of a protein complex, which transmits signals from outside to inside of cells and is as compact as possible. Thus, such proteins play an important role in the complex signal transduction of the nerve system.

On the other hand, glycoproteins present on the cell membrane are expected to function as the receptor to receive such external signals. Thus, there has been a high demand for the isolation and analysis of these membrane proteins for elucidating signal

09/831846

transduction mechanisms in the brain.

Disclosure of the Invention

5 The present invention aims to provide a novel membrane protein which is specifically expressed in the brain, a nucleic acid molecule encoding the protein, and a method for manufacturing these compounds as well as the use thereof.

Present inventors have constructed a cDNA library of 4 kb or above in size from mRNA expressed in the human adult brain, and analyzed 10 the structures of cDNAs contained in the library by the shotgun method, resulting in the successful isolation of a novel gene designated as "hh00149".

A protein encoded by the gene had a signal sequence comprising 20 amino acids, a hydrophobic amino acid region which is thought to 15 be a transmembrane domain, and further six binding sites for asparagine-bound sugar chain, indicating that this protein is one of transmembrane glycoproteins.

Northern blot analysis indicated that the hh00149 gene showed brain-specific expression. Furthermore, the hh00149 protein was 20 found to have a typical PDZ protein-binding motif comprising "serine-threonine-valine" at its carboxyl end, indicating the presence of a PDZ protein as its binding protein. A variety of proteins have been hitherto known to bind to the PDZ protein, including the ion channel, glutamate receptor, tumorigenic 25 transformation-related gene product, cell adhesion molecule, membrane-associated guanylate kinase, differentiation suppressing protein, etc. (Kornau, H.-C. et al. (1995) *Science* 269, 1737-1740; Kim, E. et al. (1995) *Nature* 378, 85-88, Matsumine et al. (1996) *Science* 272, 1020-1023, Axelrod, J. D., et al. (1996) *Science* 271, 30 1826-1832, J. Yanagisawa et al., *J. Biol. Chem.* 272, 7167-7172 (1997), H. Dong et al. (1997) *Nature* 386, 279-284), participating in various signal transduction pathways.

From such tissue-specific expression of its gene and its structural characteristics, the hh00149 protein has been suggested 35 to function as a signal transducer molecule from the outside to the inside of nerve cells.

This invention relates to a novel membrane protein specifically expressed in the brain, a nucleic acid molecule encoding the protein, and methods of preparing and using these compounds. More specifically, the invention provides the following:

- 5 (1) a DNA selected from the group consisting of the following (a) through (e):
- (a) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2;
 - 10 (b) a DNA comprising the coding region of the base sequence set forth in SEQ ID NO: 1;
 - (c) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2, which is modified by deletion and/or addition of one or more amino acid residues, and/or substitution with other amino acids, and functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID
15 NO: 2;
 - (d) a DNA hybridizing to the DNA comprising the base sequence set forth in SEQ ID NO: 1, and encoding a protein functionally equivalent to the protein comprising the amino acid sequence set
20 forth in SEQ ID NO: 2; and
 - (e) a DNA comprising a DNA according to any of (a) through (d) and a DNA encoding other peptide or polypeptide, encoding a fusion protein;
- (2) a vector inserted with the DNA according to (1);
- 25 (3) a transformant carrying the DNA according to (1) or the vector according to (2);
- (4) a protein encoded by the DNA according to (1);
- (5) a method for producing the protein according to (4), said method comprising the steps of culturing the transformant according to (3)
30 and recovering the expressed protein from said transformant or the culture supernatant thereof;
- (6) an antibody binding to the protein according to (4);
- (7) a method of screening for a compound which binds to the protein according to (4), said method comprising the steps of:
- 35 (a) bringing the protein according to (4) into contact with a sample to be tested, and

(b) selecting a compound having the activity to bind to the protein according to (4);

(8) a method for detecting or measuring the protein according to (4), said method comprising the steps of bringing the antibody according to (6) into contact with a test sample that putatively contains the protein according to (4), and detecting or measuring the formation of an immune complex of said antibody with said protein; and

(9) a polynucleotide hybridizing to the DNA comprising the base sequence according to SEQ ID NO: 1 or a complementary strand thereof and having a chain length of at least 15 bases.

The base sequence of the hh00149 cDNA isolated by the present inventors is shown in SEQ ID NO: 1, and amino acid sequence of the hh00149 protein encoded by the cDNA is shown in SEQ ID NO: 2.

The hh00149 protein of this invention has a region of sequential hydrophobic amino acids, thought to be a signal sequence, in the amino terminal 20 amino acid residues, and another hydrophobic region, which is presumed to be a transmembrane domain, located about 2/3 from the amino terminal (cf. Example 6, Fig. 3), indicating that this protein is present as a transmembrane type protein on the cell membrane. In addition, the transcriptional product of the hh00149 gene has been brain-specifically detected (cf. Example 5, Fig. 2). These facts suggest that the hh00149 protein functions especially in the brain as a signal transducer molecule to transduce a signal from the outside to the inside of cells. Therefore, the hh00149 protein can be applied to the screening of novel signal transmitters, including nerve peptides, with an expectation of its utilization in the development of remedies and diagnostics for nerve-related disorders.

The present invention also includes proteins functionally equivalent to the above-described hh00149 protein. In this invention, the term "functionally equivalent" refers to those proteins having a biological activity equivalent to the hh00149 protein. It has been demonstrated, from the analysis of binding protein using the two-hybrid system, that the hh00149 protein binds to the "149Y2H#151" protein (Japanese Patent Application No. Hei 10-331701). Therefore, the biological activity of the hh00149 protein includes its binding

activity to the "149Y2H#151" protein. In addition, a binding sequence to the PDZ protein has been detected in the hh00149 protein, suggesting the presence of PDZ proteins capable of binding to the hh00149 protein. Therefore, the biological activity of the hh00149 protein also includes its binding activity to PDZ proteins. Binding activity between proteins can be detected using, for example, the following analytical methods, such as the immunoprecipitation method and two-hybrid system of yeast.

A method for inducing mutation into the amino acid sequence of protein can be used as the method for obtaining proteins functionally equivalent to the hh00149 protein. For example, a predetermined mutation can be induced into the amino acid sequence of a protein by the method of site-specific mutagenesis, using synthetic oligonucleotide primers (Kramer, W. and Fritz, H. J. Methods in Enzymol. (1987) 154, 350-367). Mutation in the amino acid sequence can also be induced using the site-specific mutagenesis system by PCR (GIBCO-BRL). It is possible, by these methods, to obtain proteins having the amino acid sequence of the hh00149 protein (SEQ ID NO: 2) which is modified by deletion or addition of one or a plurality of amino acid residues and/or substitution with other amino acid residues, without affecting its biological activity, and functionally equivalent to the hh00149 protein. Mutation of amino acids in proteins can also occur spontaneously. Such proteins, the amino acid sequence of which are artificially or spontaneously altered, are also included in the proteins of this invention.

Specifically, proteins functionally equivalent to the hh00149 protein are exemplified by those comprising the amino acid sequence set forth in SEQ ID NO: 2 from which one or more, preferably from two to thirty, more preferably from two to ten amino acid residues are deleted, or to which one or more, preferably from two to thirty, more preferably from two to ten amino acid residues are added, or in which one or more, preferably from two to thirty, more preferably from two to ten amino acid residues are substituted with other amino acids.

It is known that a protein having an amino acid sequence which is modified by deletion or addition of one or a plurality of amino

acid residues and/or substitution of one or a plurality of amino acid residues with other amino acids can still retain its original biological activity (Mark, D. F. et al., Proc. Natl. Acad. Sci. USA (1984) 81, 5662-5666, Zoller, M. J. & Smith, M. Nucleic Acids Research 5 (1982) 10, 6487-6500, Wang, A. et al., Science 224, 1431-1433, and Dalbadie-McFarland, G. et al., Proc. Natl. Acad. Sci. USA (1982) 79, 6409-6413).

A protein with one or a plurality of amino acid residues deleted is exemplified by, for example, the hh00149 protein in the form 10 deprived of its signal peptide. On the other hand, a protein with one or a plurality of amino acid residues added is exemplified by, for example, a fusion protein containing the hh00149 protein. A fusion protein in this case is a protein consisting of the hh00149 protein fused to other peptide or protein, and is included in this 15 invention. A fusion protein can be prepared using known techniques, by ligating the DNA encoding the hh00149 protein to another DNA encoding other peptide or protein so as to be in the same reading frame, transferring the chimeric DNA to an expression vector followed by expressing it in host cells. There is no particular limitation 20 in the type of other peptides or proteins used for the fusion to the protein of this invention.

For example, known peptides used for fusion include FLAG (Hopp, T. P. et al., BioTechnology (1988) 6, 1204-1210), 6x His comprising six histidine (His) residues, 10x His, influenza hemagglutinin (HA), 25 human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40T antigen fragment, lck tag, α -tubulin fragment, B-tag, protein C fragment, etc. Proteins to be used include, for example, glutathione-S-transferase (GST), influenza hemagglutinin (HA), immunoglobulin constant region, β -galactosidase, MBP 30 (maltose-binding protein), etc.

The protein of this invention includes a protein which is encoded by a DNA hybridizing under stringent conditions to the DNA consisting of the base sequence set forth in SEQ ID NO: 1, and functionally equivalent to the hh00149 protein. Stringent hybridization 35 conditions can be appropriately selected by those skilled in the art, and are exemplified by, for example, low stringent conditions. Low

stringent conditions are, for example, at 42°C in 2x SSC and 0.1% SDS, and preferably at 50°C in 2x SSC and 0.1% SDS. More preferably, high stringent conditions may be selected, which are, for example, at 65°C in 2x SSC and 0.1% SDS. Under these conditions, as the
5 hybridization temperature is elevated, DNA with a higher homology can be obtained.

Proteins which are functionally equivalent to the hh00149 protein, and are homologous to the protein (SEQ ID NO: 2) are also included in this invention. Herein, a "homologous protein" is one
10 that has at least 70% or more, preferably at least 80% or more, more preferably at least 90% or more, and further more preferably at least 95% or more of amino acid sequence identity to that set forth in SEQ ID NO: 2. Sequence homology of proteins can be determined according to algorithm described in a literature (Wilbur, W. J. and Lipman,
15 D. J. Proc. Natl. Acad. Sci. USA (1983) 80, 726-730).

The protein of this invention may be prepared by incorporating the DNA thus obtained into an expression vector, so as to be expressible under the regulation of the expression-regulating region, for example, enhancer/promoter. Then, host cells are transformed
20 with this expression vector to express the protein.

More specifically, the process may be performed as follows. When mammalian cells are used, a commonly used useful promoter/enhancer, a DNA encoding the protein of this invention, a DNA to which the poly A signal is functionally linked downstream of the 3'-terminal of the
25 above-described DNA or a vector containing these elements is constructed. A promoter/enhancer is exemplified by, for example, the human cytomegalovirus immediate early promoter/enhancer.

In addition, other promoter/enhancer usable for protein expression includes the viral promoter/enhancer of retrovirus, polyoma virus, adenovirus, simian virus 40 (SV40), and such, and a promoter/enhancer derived from mammalian cells, such as the human elongation factor 1 α (HEF1 α).

For example, protein expression can be easily carried out according to the method of Mulligan et al. (Nature (1979) 277, 108)
35 when the SV40 promoter/enhancer is used, or the method of Mizushima et al. (Nucleic Acids Res. (1990) 18, 5322) when the HEF1 α

promoter/enhancer is employed.

When *E. coli* is used, proteins can be easily expressed by functionally ligating a commonly used useful promoter and signal sequence for the polypeptide secretion to a gene to be expressed. In this case, the promoter may be, for example, the lacZ promoter or the araB promoter. Protein expression may be achieved according to the method of Ward, et al. (Nature (1998) 341, 544-546; FASAB J. (1992) 6, 2422-2427) when the lacZ promoter is used, or the method of Better et al. (Science (1988) 240, 1041-1043) when the araB promoter is employed.

When a protein is to be produced in the periplasm of *E. coli*, the pelB signal sequence (Lei, S. P. et al., J. Bacteriol. (1987) 169, 4379) may be used as a protein secretion signal.

Replication origins derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV) and such, can also be used. Furthermore, to amplify the gene copy number in the host cell system, expression vectors may contain genes such as an aminoglycoside transferase (APH) gene, a thymidine kinase (TK) gene, a gene encoding xanthine-guanine phosphoribosyltransferase of *E. coli* (Ecogpt) and a dihydrofolate reductase (dhfr) gene, as selective markers.

Any expression vector may be used to produce the protein of this invention so long as they are preferably used in this invention. Expression vectors used in this invention include those derived from mammals such as pEF and pCDM8, (those derived) from insect cells such as pBacPAK8, (those derived) from plants such as pMH1 and pMH2, (those derived) from animal viruses such as pHSV, pMV and pAdexLcw, (those derived) from retroviruses such as pZIpneo, (those derived) from yeast such as pNV11 and SP-Q01, (those derived) from *Bacillus subtilis* such as pPL608 and pKTH50, and (those derived) from *E. coli* such as pQE, pGEAPP, pGEMEAPP and pMALp2.

Expression vectors of this invention constructed as described above are transferred to host cells using known methods, for example, the calcium phosphate method (Virology (1973) 52, 456-467), the electroporation method (EMBO J. (1982) 1, 841-845), and the like.

In this invention, any production systems can be used for the protein manufacturing. For the protein production, there are in

vitro and *in vivo* production systems. The *in vitro* production systems include those using eukaryotic cells and prokaryotic cells.

When eukaryotic cells are used, there are protein production systems using cells of animals, plants or fungi. Animal cells commonly used are mammalian cells, for example, CHO cell (J. Exp. Med. (1995) 108, 945), COS cell, myeloma cell, BHK (baby hamster kidney) cell, HeLa cell and Vero cell, amphibian cells, for example, oocytes of *Xenopus laevis* (Valle, et al., Nature (1981) 291, 358-340) or insect cells, for example, sf9, sf21 and Tn5 cells. Of CHO cells, especially those deficient of the DHFR gene, dhfr-CHO cell (Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) and CHO K-1 cell (Proc. Natl. Acad. Sci. USA (1968) 60, 1275), are preferably used.

Known plant cells used for protein production are those derived from *Nicotiana tabacum*, which can be cultured as callus. Fungus cells commonly used include yeast, belonging to, for example, the genus *Saccharomyces* such as *Saccharomyces cerevisiae*, and filamentous fungus of, for example, the genus *Aspergillus* such as *Aspergillus niger*.

When prokaryotic cells are used, there are systems using bacterial cells. *E. coli* and *Bacillus subtilis* are known bacterial cells.

Proteins can be obtained by transforming these cells with the desired DNA, and culturing the thus transformed cells *in vitro*. Cell culturing is performed according to known methods. DMEM, MEM, RPMI1640 and IMDM can be used as the culture medium. In this case, serum supplements, such as fetal calf serum (FCS), can be used together, or the culture may be performed in a serum-free medium. The pH during cultivation is preferably in the range of about 6 to 8. Culture is usually carried out at about 30 to 40°C for about 15 to 200 hr, with the exchange of medium, aeration and agitation as the occasion demands.

On the other hand, *in vivo* production systems include those using animals and plants. These animals or plants are transfected with a desired DNA to produce a protein in the body of animal or plant and the protein product is collected. "Host" in this invention includes these animals and plants.

When animals are used, there are production systems using mammals and insects. Goats, pigs, sheep, mice and cattle can be used as mammals (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). In addition, when mammals are used, transgenic animals can be also used.

For example, a desired DNA is inserted in the middle of a gene encoding a protein specifically produced in milk, such as the goat β -casein, to prepare a fusion gene. A DNA fragment containing this fusion gene inserted with the desired DNA is injected into a goat embryo, which is then implanted in the uterus of a female goat. The desired protein is obtained from the milk produced by the transgenic goat born from the goat which accepted the embryo or its offspring. To increase the yield of milk containing the protein produced by the transgenic goat, a suitable hormone may be appropriately administered to transgenic goats (Ebert, K. M. et al., Bio/Technology (1994) 12, 699-702).

In addition, insects, for example, silkworm can be used. In this case, silkworms are infected with the baculovirus inserted with a desired DNA, and the desired protein is obtained from their body fluid (Susumu, M. et al., Nature (1985) 315, 592-594).

Furthermore, when plants are used, tobacco, for example, can be employed. In the case of use of tobacco, a desired DNA is inserted into a plant expression vector, for example, pMON 530, and this vector is then transferred into a bacterium such as *Agrobacterium tumefaciens*. A tobacco plant, for example, *Nicotiana tabacum*, is infected with this bacterium, from leaves of which the desired protein is obtained (Julian, K. -C. Ma et al., Eur. J. Immunol. (1994) 24, 131-138).

Proteins of this invention thus obtained can be isolated from the inside and outside of cells or hosts, and purified to essentially pure and homogeneous protein preparations. Isolation and purification of proteins can be performed using conventional isolation and purification methods for usual proteins, and are not restricted in any way. For example, proteins can be isolated and purified by appropriate selection and combination of the following tools and techniques like chromatography column, filter,

ultrafiltration, salting-out, precipitation with solvent, extraction with solvent, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc.

5 Examples of chromatography include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, adsorption chromatography, etc. (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed. Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographies can be carried out using liquid phase chromatography, for example, HPLC, FPLC, etc. This invention also includes proteins highly purified using these purification methods.

15 The optional modification to the protein or the removal of partial peptide therefrom can be performed by reacting proteins before or after the purification with the appropriate protein modification enzyme. Trypsin, chymotrypsin, lysyl endopeptidase, protein kinase and glucosidase are commonly used protein modification enzymes.

20 This invention also includes partial peptides of the hh00149 protein (SEQ ID NO: 2). The partial peptides include, for example, those corresponding to the binding site for other proteins, such as the 149Y2H#151 protein and PDZ protein out of partial peptide sequences encoded by the hh00149 gene. These partial peptides can be used for the inhibition and so on of the signal transduction via the hh00149 protein.

30 Partial peptides of this invention can be prepared by genetic engineering techniques, known peptide synthesis method, or cleavage of the protein of this invention with a suitable peptidase. Peptide synthesis may be performed by either the solid phase or liquid phase synthesis method.

35 The present invention also relates to DNAs encoding the above-described proteins of this invention. DNAs of this invention are not only used for the production of proteins of this invention as described above but also may be applied to gene therapy, and such, for disorders caused by abnormalities of the gene encoding proteins

of this invention.

cDNAs encoding the proteins of this invention can be obtained, for example, by screening human cDNA libraries using the probes described in this specification.

5 Other cDNAs can be obtained from different cells, tissues, organs or species by further screening cDNA libraries with those cDNAs thus obtained or fragments thereof as probes. cDNA libraries may be prepared by the method described in, for example, Sambrook, J. et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (1989),
10 or commercially available DNA libraries may be used instead.

Furthermore, the sequencing of cDNA thus obtained enables the determination of the translation region encoded by the cDNA and the elucidation of amino acid sequence of the protein of this invention. In addition, the genomic DNA can be isolated by screening the genomic
15 DNA library with cDNAs thus obtained as probes.

Specifically, the following procedures may be used. First, mRNA is isolated from cells, tissues or organs expressing the protein of this invention. For the isolation of mRNA, the total RNA is prepared by known methods, for example, the guanidine ultracentrifugation
20 method (Chirgwin, J. M. et al., Biochemistry (1979) 18, 5294-5299), the AGPC method (Chomczynski, P. and Sacchi, N., Anal. Biochem. (1987) 162, 156-159), and such, and mRNA is then purified from the total RNA using an mRNA Purification Kit (Pharmacia), etc. mRNA can be also directly prepared using a QuickPrep mRNA Purification Kit
25 (Pharmacia).

cDNA is synthesized from mRNA thus obtained using the reverse transcriptase. Synthesis of cDNA can also be performed using an AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Kogyo). cDNA can also be synthesized and amplified according to the
30 5'-RACE method (Frohman, M. A. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998-9002; Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932) using a 5'-Ampli FINDER RACE Kit (Clontech) and the polymerase chain reaction (PCR) with probes described in this specification.

35 The desired DNA fragments are prepared from PCR products thus obtained, and ligated to a vector DNA. Then, a recombinant vector

is prepared, transferred into *E. coli*, and such, and colonies are selected to prepare the desired recombinant vector. Base sequence of the desired DNA may be confirmed by known methods, for example, the dideoxynucleotide chain termination method.

5 Furthermore, the sequence for a higher expression efficiency can be designed for the DNA of this invention, considering the frequency of codon used by the host to be used for expression (Grantham, R. et al., *Nucleic Acids Research* (1981) 9, p43-74). DNAs of this invention can be modified using commercially available kits and known
10 methods. For example, these modifications include the digestion with restriction enzymes, the insertion of synthetic oligonucleotides and suitable DNA fragments, the ligation of linkers, the insertion of the initiation codon (ATG) and/or termination codon (TAA, TGA or TAG), etc.

15 Specifically, the DNA of this invention includes DNAs encoding the protein comprising the amino acid sequence set forth in SEQ ID NO: 2 and mutants thereof described above. A preferred DNA comprises the base sequence extending from base 466 (A) to base 2832 (C) in the base sequence shown in SEQ ID NO: 1.

20 DNAs of this invention also include DNAs which hybridize under stringent conditions to the DNA consisting of the base sequence set forth in SEQ ID NO: 1, and encoding proteins functionally equivalent to the above-described proteins of this invention.

Stringent hybridization conditions can be appropriately
25 selected by those skilled in the art, including, for example, low stringent conditions. Low stringent conditions refer to, for example, hybridization at 42°C and washing in 2x SSC and 0.1% SDS, and preferably at 50°C and in 2x SSC and 0.1% SDS. Yet more preferably, high stringent conditions may be selected. High stringent conditions
30 refer to, for example, hybridization at 65°C and washing in 2x SSC and 0.1% SDS. Under these conditions, as the hybridization temperature is elevated, DNA with a higher homology can be obtained. The above-described DNAs to be hybridized are preferably cDNA or chromosomal DNA.

35 Proteins of this invention are useful for screening compounds binding to protein. That is, the proteins are used in the method

of screening for compounds that bind to the proteins of this invention, in which the method comprises bringing proteins of this invention into contact with a test sample that is expected to contain a compound to bind to the proteins and selecting a compound with the activity to bind to the proteins of this invention.

Proteins of this invention used in the screening may be any of recombinant, natural or partial peptides. Also they may be a purified protein, partial peptides thereof, or in the form of proteins expressed on the cell surface or membrane fractions.

Samples to be tested in the screening method of this invention may include, for example, peptides, purified or crude proteins, non-peptidic compounds, synthetic compounds, fermentation products of microorganisms, cell extracts, animal tissue extracts, marine creature extracts and plant extracts. Samples to be tested may be those naturally occurring or artificially synthesized.

Screening of proteins binding to the proteins of this invention can be carried out, for example, by the immunoprecipitation method. Specifically, the method can be carried out as follows. The gene encoding the protein of this invention is expressed by inserting the gene downstream of the promoter of foreign gene expression in pSV2neo, pCDNA I, pCD8, and such, and expressing the gene in animal cells, etc. Any generally used promoters may be employed for the expression, including the SV40 early promoter (Rigby In Williamson (ed.), Genetic Engineering, Vol. 3. Academic Press, London, p.83-141 (1982)), EF-1 α promoter (Kim, et al. Gene 91, p. 217-223 (1990)), CAG promoter (Niwa, et al. Gene 108, p. 193-200 (1991)), RSV LTR promoter (Cullen, Methods in Enzymology 152, p.684-704 (1987)), SR α promoter (Takebe et al., Mol. Cell. Biol. 8, p.466 (1988)), CMV immediate early promoter (Seed and Aruffo Proc. Natl. Acad. Sci. USA 84, p. 3365-3369 (1987)), SV40 late promoter (Gheysen and Fiers J. Mol. Appl. Genet. 1, p.385-394 (1982)), Adenovirus late promoter (Kaufman et al., Mol. Cell. Biol. 9, p.946 (1989)), HSV TK promoter, etc. Transfer of a foreign gene into animal cells for its expression can be performed by any of the following methods, including the electroporation method (Chu, G. et al., Nucl. Acid Res. 15, 1311-1326 (1987)), the calcium phosphate method (Chen, C. and Okayama, H. Mol. Cell. Biol. 7,

2745-2752 (1987)), the DEAE dextran method (Lopata, M. A. et al. Nucl. Acids Res. 12, 5707-5717 (1984); Sussman, D. J. and Milman, G. Mol. Cell. Biol. 4, 1642-1643 (1985)), the lipofectin method (Derijard, B. Cell. 7, 1025-1037 (1994); Lamb, B. T. et al. Nature Genetics 5, 22-30 (1993)), Rabindran, S. K. et al. Science 259, 230-234 (1993)), etc. The protein of this invention can be expressed as a fusion protein having the recognition site for a monoclonal antibody by introducing the recognition site (epitope) for a monoclonal antibody, the specificity of which has been established, into the N- or C-terminal of the protein of this invention. For this purpose, a commercial epitope-antibody system can be utilized (Jikken Igaku (Experimental Medicine) 13, 85-90 (1995)). Vectors are commercially available which are capable of expressing fusion proteins with β -galactosidase, maltose-binding protein, glutathione S-transferase, green fluorescence protein (GFP), and such, via the multi-cloning site.

To minimize the alteration in properties of the protein of this invention due to the fusion protein formation, there has been reported a method for preparing a fusion protein by introducing only a small epitope portion comprising several to ten amino acid residues. For example, the epitopes of polyhistidine (His-tag), influenza hemagglutinin (HA), human c-myc, FLAG, Vesicular stomatitis virus glycoprotein (VSV-GP), T7 gene 10 protein (T7-tag), human herpes simplex virus glycoprotein (HSV-tag), E-tag (epitope on the monoclonal phage), and such, and monoclonal antibodies to recognize these epitopes can be utilized as the epitope-antibody system for screening proteins binding to the protein of this invention (Jikken Igaku (Experimental Medicine) 13, 85-90 (1995)).

In the immunoprecipitation, immune complexes are formed by adding these antibodies to the cell lysate prepared using suitable surfactants. This immune complex comprises a protein of this invention, a protein capable of binding to the protein, and an antibody. The immunoprecipitation can also be performed using an antibody to a protein of this invention besides antibodies to the above-described epitopes. An antibody to a protein of this invention can be prepared by inserting a gene encoding a protein of this

invention into an appropriate expression vector of *E. coli* to express it in the bacterium, purifying the protein thus expressed, and immunizing rabbits, mice, rats, goats, chicken, and such, with the purified protein. The antibody can also be prepared by immunizing
5 the above-described animals with partial peptides of the protein of this invention.

Immune complexes can be precipitated using, for example, Protein A Sepharose and Protein G Sepharose in case that the antibody is a murine IgG antibody. In addition, in the case where the protein of
10 this invention is prepared as a fusion protein with the epitope of, for example, GST, and such, the immune complex can be formed using a substance that specifically binds to these epitopes, such as glutathione-Sepharose 4B, and such, giving the same result as in the case where the antibody for the protein of this invention is used.

15 Immune precipitation, in general, may be carried out according to, or following the method described in the literature (Harlow, E. and Lane, D.: *Antibodies*, pp.511-552, Cold Spring Harbor Laboratory publications, New York (1988)).

SDS-PAGE is generally used for the analysis of
20 immunoprecipitated proteins. Bound proteins can be analyzed based on the molecular weights of proteins using a gel of an appropriate concentration. In this case, although proteins bound to the protein of this invention, in general, are hardly detectable by the usual protein staining method, such as Coomassie staining and silver
25 staining, the detection sensitivity can be improved by culturing cells in a medium containing the radio isotope-labeled ³⁵S-methionine and ³⁵S-cysteine to label proteins inside the cells, and detecting the labeled proteins. Once the molecular weight of the protein is determined, the desired protein can be purified directly from
30 SDS-polyacrylamide gel and sequenced.

And, another embodiment of screening of this invention is exemplified by a method utilizing the 2-hybrid system using cells (Fields, S., and Sternglanz, R., *Trends. Genet.* (1994) 10, 286-292).

35 Herein, a 2-hybrid system can be used, in which (1) an expression vector containing a first DNA encoding a fusion protein, comprising the protein of this invention and one of the subunits of a

heterodimeric transcriptional regulatory factor, and (2) another expression vector containing a second DNA, comprising a desired cDNA as the test sample ligated to a DNA encoding another subunit of the heterodimeric transcriptional regulatory factor, is introduced into
5 cells, and expressed, so that when the protein encoded by the cDNA binds to the protein of this invention to allow the transcriptional regulatory factor to form a heterodimer, the reporter gene previously constructed within the cells is expressed. Alternatively, another 2-hybrid system can be used, in which a transcriptional regulatory
10 factor, such as the yeast GAL4 protein having a DNA-binding domain and a trans-activation domain, is separated by each domain, a first expression vector containing DNA encoding the fusion protein, comprising the DNA-binding domain of the transcriptional regulatory factor and the protein of this invention, and a second expression
15 vector, containing DNA comprising a desired cDNA as the test sample ligated to DNA encoding the trans-activation domain of the transcriptional regulatory factor, are introduced into cells and expressed, so that when the protein encoded by the cDNA binds to the protein of this invention to allow the transcriptional regulatory
20 factor to form a heterodimer, the reporter gene previously constructed within the cells is expressed. When there is a protein capable of binding to the protein of this invention, the protein can be sorted out by detecting or measuring the expression amount of the reporter gene.

25 More specifically, the process may be performed as follows. That is, DNA encoding the protein of this invention is ligated to the DNA encoding the DNA-binding domain of LexA, so that they are in the same reading frame to form a first expression vector. Next, a second expression vector is formed by ligating a desired cDNA to the gene
30 encoding the trans-activation domain of GAL4.

After the cells integrated with the HIS3 gene the transcription of which is regulated by the promoter having the LexA-binding motif are transformed with the above-described expression plasmids of the 2-hybrid system, they are incubated in a histidine-free synthetic
35 medium. In this case, cell growth is observed only when the interaction between proteins occurs. Thus, an increase in the

expression amount of reporter gene can be assessed by the growth extent of the transformant. Besides the HIS3 gene, the Ade2 gene, the LacZ gene, the CAT gene, the luciferase gene, and such, can be used as the reporter gene.

5 The 2-Hybrid system can be constructed using a conventional method, or using commercial kits instead. Commercially available 2-hybrid system kits include a MATCHMARKER Two-Hybrid System, Mammalian MATCHMAKER Two-Hybrid Assay Kit (both from CLONTECH), HybriZAP Two-Hybrid Vector System (Stratagene).

10 In fact, receptor-protein interactions involved in the ion channel and signal transduction having the PDZ domain have been demonstrated using the 2-bybrid system of yeast, including the binding of APC to hDLG (A. Matsumine et al. Science 272, 1020-1023 (1996)), the binding of GRIP to the AMPA receptor (H. Dong et al. 15 Nature 386, 279-284 (1997)), the binding of Homer to the glutamate receptor (P. R. Brakeman et al. Nature 386, 284-288 (1997)), the binding of SRY to SIP-1 (F. Poulat et al. J. Biol. Chem. 272, 7167-7172 (1997)), etc.

In addition, screening of proteins binding to the protein of this 20 invention can be also performed using the West-western blotting method (Skolnik, E. Y. et al., Cell (1991) 65, 83-90). Namely, cDNA is isolated from cells, tissues and organs in which protein capable of binding to the protein of this invention is expected to be expressed, and transferred into a phage vector, for example, *egt11*, 25 ZAPII, and such, to prepare a cDNA library, which is then expressed on plates coated with a growth medium. The protein thus expressed is fixed on a filter, which is then reacted with the labeled, purified protein of this invention, and plaques expressing a protein bound to the protein of this invention can be detected by the label. Methods 30 for labeling the protein of this invention include methods utilizing the binding activity of biotin and avidin, methods utilizing antibodies specifically binding to the protein of this invention, or peptides or polypeptides fused with the protein of this invention, methods utilizing the radioisotopes, methods utilizing fluorescence, 35 etc.

Screening for compounds which bind to the protein of this

invention can be also carried out using affinity chromatography. The protein of this invention is immobilized on the carrier in the affinity chromatography column, to which a test sample, which is expected to express a protein capable of binding to the protein of this invention, is applied. After applying the test sample, the column is washed, and protein which binds to the protein of this invention can be obtained.

Compounds isolated by the above-described screening method can be candidates for drugs to stimulate or suppress the activity of the protein of this invention in disorders caused by its functional abnormalities, etc. Compounds, which are obtained by the screening method of this invention and which have the activity to bind to the protein of this invention, the partial structure of which is modified by addition, deletion and/or substitution (of amino acid residues), are also included in compounds obtained by the screening method of this invention.

When compounds obtained using the screening method of this invention are used as drugs for humans and mammals, for example, mice, rats, guinea pigs, rabbits, chickens, cats, dogs, sheep, pigs, cattle, monkeys, baboons and chimpanzees, they can be administered according to commonly used means.

The compounds can be administered, as the occasion demands, orally, as sugar-coated tablets, capsules, elixirs and microcapsules, or parenterally, in the form of sterile solutions in water or other pharmaceutically acceptable liquids, or suspensions for injections. For example, drugs can be manufactured by mixing substances having the activity to bind to the protein of this invention with physiologically acceptable carriers, seasonings, excipients, vehicles, anticeptics, stabilizers and binders in the unit dosage form required in a generally accepted pharmaceutical procedure. Amounts of effective ingredients in these pharmaceutical preparations are adjusted so as to obtain the appropriate dose in the specified range.

Additives which can be mixed in tablets and capsules include, for example, binders such as gelatin, corn starch, tragacanth gum and arabic gum, excipients such as crystalline cellulose, bulking

agents such as corn starch, gelatin and alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose, lactose or saccharine, and flavors such as peppermint, *Gaultheria adeno-thrix* oil or cherry. When the dispensing unit form is a capsule, liquid carriers, such as oil, can be further added to the above-described materials. Sterile compositions for injection can be prescribed using vehicles such as distilled water for injection according to standard pharmaceutical procedure.

Aqueous solutions for injections include, for example, physiological saline and isotonic solutions containing glucose and other supplements such as D-sorbitol, D-mannose, D-mannitol, sodium chloride, and such, and suitable solubilizers, for example, alcohols, more specifically, ethanol, polyalcohols such as propylene glycol, polyethylene glycol, non-ionic surfactants such as polysorbate 80 (TM) and HCO-50 may be used together.

Oily solutions, including sesame oil and soybean oil, and benzyl benzoate and benzyl alcohol may be used together as the solubilizer. Injections may be combined with buffers such as phosphate buffer and sodium acetate buffer, soothing agents such as procaine hydrochloride, stabilizers such as benzyl alcohol, phenols and antioxidants. Injections thus prepared are typically filled in suitable ampules.

Though they vary depending on the symptoms, doses of compounds having the activity to bind to the protein of this invention are in the range of about 0.1 to 100 mg, preferably about 1.0 to 50 mg, and more preferably about 1.0 to 20 mg per day for adults (based on the body weight 60 kg) in the case of oral administration.

Though it varies depending on the subject to be administered, target organ, symptom and method of administration, a single dose of the compounds for the parenteral administration is preferably administered, for example, when it is in the form of injection, intravenously to normal adults (based on the body weight 60 kg) in the range of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg or thereabout per day. Doses converted on the 60 kg body weight basis can be similarly administered to other animals.

Antibodies of this invention can be obtained as monoclonal or polyclonal antibodies by known means.

Antibodies specifically binding to the protein of this invention can be prepared by immunizing suitable animals with protein used as the antigen according to a usual immunization method, fusing immunocytes thus obtained with known parent cells by a usual cell fusion method, and screening antibody-producing cells by an ordinary screening method.

Specifically, monoclonal or polyclonal antibodies which specifically binds to the protein of this invention may be prepared as follows.

For example, the protein of this invention used as the antigen for obtaining antibodies, though there is no limitation in animal species from which it is derived, is preferably a protein derived from mammals, for example, humans, mice or rats, especially from humans, which can be obtained using the gene sequence or amino acid sequence disclosed in the present specification.

In this invention, proteins having the biological activities of the proteins described in this specification can be used as the antigen. Partial peptides of these proteins can be also used as the antigen. These partial peptides of the protein include, for example, the amino (N)-terminal fragments and carboxyl terminal (C) fragments of the protein. "Antibody" as described in this specification means an antibody specifically reacting with the full length protein or fragments thereof.

After inserting the gene encoding the protein of this invention or fragments thereof into a known expression vector and transforming host cells described in this specification with this recombinant vector, the desired protein or fragments thereof are obtained from inside and outside host cells or from host cells by a standard method. These proteins may be used as the antigen. Cells expressing the protein or the lysate thereof, or the chemically synthesized protein of this invention may also be used as the antigen.

Although there is no limitation in species of mammals to be immunized with the antigen, it is preferable to take into consideration the compatibility with parent cells used for cell

fusion, and animals of the rodent, lagomorph and primate are generally used.

For example, mice, rats, hamsters, and such, are used among the rodent animals, rabbits among lagomorphic animals, and monkeys among
5 primate animals. Among monkeys, catarrhine monkeys (old world monkeys), for example, *Macaca fascicularis*, rhesus monkey, baboon, chimpanzee and such are used.

Immunization of animals with antigens is carried out according to any known method. For example, immunization in general is
10 performed by the intraperitoneal or subcutaneous injection of the antigen to mammals. Specifically, the antigen is diluted or suspended to the appropriate amount in PBS (Phosphate-Buffered Saline) or physiological saline, mixed with suitable amount of usual adjuvant, for example, Freund's complete adjuvant, as the occasion
15 demands, emulsified, and then administered to mammals, favorably followed by several booster injections of the antigen mixed with an appropriate amount of Freund's incomplete adjuvant every 4~21 days. In addition, suitable carriers can be used at the time of immunization with the antigen. Elevation of levels of the desired antibody in
20 the sera of animals thus immunized is confirmed by a standard method.

Herein, polyclonal antibodies to the protein of this invention are obtained by withdrawing the blood of mammals sensitized with the antigen after confirming the elevation of levels of desired antibody in the serum, and isolating the serum from the blood by a known method.
25 Serum containing polyclonal antibody may be used as the polyclonal antibody, or fractions containing polyclonal antibody may be further isolated from the serum as the occasion demands.

Monoclonal antibodies can be obtained by removing immunocytes from the mammals, after confirming the elevation of levels of desired
30 antibody in the serum of mammals sensitized with the above-described antigen, and subjecting them to cell fusion. In this case, immunocytes preferably used for cell fusion are spleen cells in particular. Parent cells to be fused to the above-described immunocytes are preferably mammalian myeloma cells, more preferably
35 myeloma cells which have acquired characteristics for the selection of fused cells by drugs.

Cell fusion of the above-described immunocytes and myeloma cells can be carried out according to a known method, for example, the method of Milstein et al. (Galfre, G. and Milstein, C., *Methods Enzymol.* (1981) 73, 3-46), etc.

5 Hybridomas thus obtained by cell fusion are selected by culturing them in a standard selection medium, for example, the HAT culture medium (culture solution containing hypoxanthine, aminopterin and thymidine). Culturing in the HAT medium is continued for a sufficient
10 time required for killing other cells (non-fused cells) than desired hybridomas, usually for several days to several weeks. Then, a usual limiting culture-dilution method is applied for carrying out screening and cloning of hybridomas producing the desired antibody.

In addition to the above-described hybridomas obtained by immunizing animals other than humans with the antigen, human
15 lymphocytes, for example, human lymphocytes infected with the EB virus, are sensitized with a protein, protein expressing cells or lysates thereof *in vitro*, and the sensitized lymphocytes are fused with human-derived myeloma cells having a permanent proliferation
20 potency, for example, U266 cells, to obtain hybridomas capable of producing the desired human antibody having the activity to bind to the protein (Unexamined Published Japanese Patent Application No. Sho 63-17688).

Furthermore, human antibodies against a protein may be obtained by immunizing transgenic animals having a repertoire of human
25 antibody genes with an antigenic protein, cells expressing the protein or lysate thereof, to obtain antibody-producing cells, and fusing these cells to myeloma cells to prepare hybridomas, which are used to obtain human antibody against the protein (cf. International Patent Application Nos. WO92-03918, WO93-2227,
30 WO94-02602, WO94-25585, WO96-33735 and WO96-34096).

Besides the production of antibody using hybridoma, immunocytes, such as sensitized lymphocytes, and such, producing antibody which is immortalized with oncogenes may be used for the antibody
production.

35 Monoclonal antibodies thus obtained can be also prepared as a recombinant antibody, using genetic recombination techniques (cf.,

for example, Borrebaeck, C. A. K. and Larrick, J. W., THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). A recombinant antibody is produced by cloning DNA encoding the protein from hybridoma or immunocytes such as sensitized lymphocytes producing the antibody, incorporating the DNA into appropriate vector, and transferring the vector into host cells. This recombinant antibody is also included in this invention.

Antibodies of this invention may also include fragments and modified products of the antibody, so long as they are capable of binding to the protein of this invention. For example, the antibody fragments include Fab, F(ab')₂, Fv or a single-chained Fv (scFv) prepared by linking the H-chain to the Fv of L-chain via a suitable linker (Huston, J. S. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 5879-5883). Specifically, antibody fragments are produced by digesting the antibody with enzymes, for example, papain or pepsin, or by constructing a gene encoding these fragments, inserting the gene into an expression vector, and expressing it in suitable host cells (cf., for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A. H., Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzymol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; Bird, R. E. and Walker, B. W., Trends Biotechnol. (1991) 9, 132-137).

Antibody bound to various molecules, such as polyethylene glycol (PEG), and such, can be also used as the modified antibody. The "antibody" of this invention also includes these modified antibodies. These modified antibodies can be prepared by chemically modifying the antibody obtained as above. These modification methods have been already established in this field.

In addition, the antibody of this invention can be obtained, using known techniques, as a chimeric antibody comprising the variable region derived from a non-human antibody and the constant region derived from a human antibody, or a humanized antibody comprising the CDR (complementary-determining region) derived from a non-human antibody, the FR (framework region) and the constant region derived from a human antibody.

Antibodies obtained as described above can be purified to homogeneity. For the isolation and purification of the antibody used in this invention, any methods of isolation and purification used for ordinary proteins can be applied without limitation.

5 Concentration of the antibody obtained as described above can be determined by the measurement of absorbance or the enzyme-linked immunosorbent assay (ELISA), etc.

Furthermore, ELISA, EIA (enzyme immunoassay), RIA (radioimmunoassay) or fluorescent antibody technique can be used as
10 the methods for measuring the antigen-binding activity of the antibody of this invention. For example, when ELISA is used, the protein of this invention is added to plates on which the antibody of this invention has been immobilized, and then a sample containing the desired antibody, for example, the culture supernatant of
15 antibody-producing cells or purified antibody is added to the plates. A secondary antibody labeled with an enzyme, for example, alkaline phosphatase and such, to recognize the antibody is added to the plates. After incubating and washing the plates, the enzyme substrate such as p-nitrophenyl phosphate, and such, is added to measure the
20 absorbance, so that the antigen-binding activity can be assessed. In place of a whole protein, its fragments, for example, fragments comprising its C-terminal or N-terminal, may be used. For the activity assay of the antibody of this invention, BIAcore (Pharmacia) can be used.

25 A method for detecting and measuring the protein of this invention can be carried out by using these techniques, the method comprising bringing the antibody of this invention into contact with a sample which is expected to contain the protein of this invention, and detecting or measuring an immune complex consisting of the
30 antibody and the protein.

Since the method of this invention for detecting or measuring proteins is capable of selectively detecting or measuring proteins, it is useful for various experiments and such, using proteins.

35 The present invention includes polynucleotides hybridizing to a DNA comprising a base sequence set forth in SEQ ID NO: 1 or a DNA complementary to the DNA, and consisting of at least 15 bases. That

is, this invention includes probes, nucleotides or nucleotide derivatives, for example, antisense-oligonucleotides, ribozymes, and such, which are capable of selectively hybridizing to a DNA encoding the protein of this invention or a DNA complementary to the
5 DNA.

This invention includes an antisense oligonucleotide, for example, hybridizing to any site of the base sequence set forth in SEQ ID NO: 1. This is preferably an antisense oligonucleotide to a nucleotide comprising at least 15 or more consecutive nucleotides
10 in the base sequence set forth in SEQ ID NO: 1. More preferably, the antisense oligonucleotide comprises at least 15 or more consecutive bases containing the translation initiation codon.

Derivatives and modified products of antisense oligonucleotides can be used as the antisense oligonucleotide. Such modified products
15 include those modified with low alkyl phosphonates, such as the methyl phosphonate type and ethyl phosphonate type, those modified with phosphorothionate or phosphoroamidate, etc.

Herein, "antisense oligonucleotide" includes not only nucleotides corresponding to those constituting a predetermined
20 region of a DNA or mRNA of which are all complementary to the DNA or mRNA, but also nucleotides having one or a plurality of mismatched nucleotides so far as they can selectively as well as stably hybridize to the base sequence set forth in SEQ ID NO: 1.

Herein, the phrase "selectively and stably hybridize" means that
25 a DNA does not significantly cross-hybridize to other DNAs encoding other proteins under usual hybridization conditions, preferably under a stringent hybridization conditions. Such a polynucleotide refers to the one which has a base sequence of at least 15 consecutive nucleotides, and has at least 70% or more, preferably at least 80%
30 or more, more preferably at least 90% or more, and further more preferably at least 95% or more of base sequence identity to a nucleotide to be hybridized. Algorithms described in this specification can be used to determine the sequence homology. Such polynucleotides are useful, as described below in examples, as probes
35 for detecting or isolating a DNA encoding the protein of this invention or as primer for amplifying the DNA.

Derivatives of antisense oligonucleotides of this invention have a suppressive effect on the action of the proteins of this invention resulting from the repression of the expression of the protein caused by their action on cells producing the protein of this invention and
5 binding to DNA or mRNA encoding the protein to suppress the transcription or translation thereof or enhance the decomposition of mRNA.

Derivatives of antisense oligonucleotides of this invention can be mixed with appropriate bases inert to them to prepare the external
10 preparation such as salve, cataplasm, etc.

In addition, as the occasion demands, excipients, isotonicity agents, solubilizers, stabilizers, antiseptics, soothing agents, and such, are added to the above-described derivatives to prepare
15 tablets, powder agents, granules, capsules, liposome capsules, injection agents, liquid preparations, nasal drops, and such, and further lyophilized preparations. They can be prepared according to a standard method.

Derivatives of antisense oligonucleotides of this invention are either directly applied to the affected region of patient or
20 intravascularly administered, for example, to patient, so that they can eventually reach the affected region. Furthermore, antisense nucleotide enclosing materials can be used to enhance the durability or membrane permeability, including liposome, poly-L-lysine, lipid, cholesterol, lipofectin, or derivatives thereof.

Doses of derivatives of antisense oligonucleotides of this invention can be appropriately adjusted according to the conditions
25 of patients, and used in preferable amounts. For example, they can be administered in the range 0.1~100 mg/kg, preferably 0.1~50 mg/kg.

The antisense oligonucleotides of this invention inhibit the
30 expression of the protein of this invention and, thus, are useful for suppressing its biological activities. Expression inhibitors comprising antisense oligonucleotides of this invention are useful in that they can suppress biological activities of the protein of this invention.

35

Brief Description of the Drawings

Fig. 1 represents a photograph showing the results of Northern blot analysis of the hh00149 gene.

"H" in the figure represents the results of detection obtained using Human MTN Blot (CLONTECH, catalogue No. 7760-1), showing 1. heart, 2. brain, 3. placenta, 4. lung, 5. liver, 6. skeletal muscle, 7. kidney and 8. Pancreas. "H4" represents the results of detection obtained using Human MTN Blot IV (CLONTECH, catalogue No. 7766-1), showing 1. spleen, 2. thymus, 3. prostate, 4. testis, 5. uterus, 6. small intestine, 7. colon and 8. peripheral lymphocyte.

10 "F" represents the results of detection using Human Fetal MTN Blot II (CLONTECH, catalogue No. 7756-1), showing 1. fetal brain, 2. fetal lung, 3. fetal liver and 4. fetal kidney.

"C" represents the results of detection using Human Cancer Cell Line MTN Blot II (CLONTECH, catalogue No. 7757-1), showing 1. acute leukemia HL-60 cell, 2. HeLa cell S3, 3. chronic myelocytic leukemia K-562 cell, 4. lymphoblastic leukemia MOLT-4 cell, 5. Burkitt's lymphoma Raji cell, 6. colorectal adenocarcinoma SW-480 cell, 7. lung cancer A549 cell and 8. melanoma G361 cell, respectively.

20 "B2" represents the results of detection using Human Brain MTN Blot II (CLONTECH, catalogue No. 7755-1), showing 1. cerebellum, 2. cerebral cortex, 3. medulla oblongata, 4. spinal cord, 5. occipital lobe, 6. frontal lobe, 7. temporal lobe and 8. putamen, respectively.

"B4" represents the results of detection using Human Brain MTN Blot IV (CLONTECH, catalogue No. 7769-1), 1. cerebellar tonsil, 2. caudatum, 3. corpus callosum, 4. hippocampus, 5. whole brain, 6. nigra and 7. thalamus.

Fig. 2 represents photographs showing the results of RT-PCR. The first strand cDNAs used were 32 in total, derived from 1. brain, 2. heart, 3. kidney, 4. liver, 5. lung, 6. pancreas, 7. placenta, 8. skeletal muscle, 9. large intestine, 10. ovary, 11. peripheral lymphocyte, 12. prostate, 13. small intestine, 14. spleen, 15. testis, 16. thymus, 17. fetal brain, 18. fetal heart, 19. fetal kidney, 20. fetal liver, 21. fetal lung, 22. fetal skeletal muscle, 23. fetal spleen, 24. fetal thymus, 25. breast carcinoma (GI-101), 26. lung carcinoma (LX-1), 27. colon adenocarcinoma (CX-1), 28. lung carcinoma (GI-117), 29. prostatic adenocarcinoma (PC-3), 30. colon

adenocarcinoma (GI-112), 31. ovarian carcinoma (GI-102) and 32. pancreatic adenocarcinoma (GI-103) (CLONTECH, catalogue Nos. K1420-1, K1421-1, K1425-1, and K1422-1). Results of RT-PCR for detecting the hh-00149 gene and G3PDH gene (control) are indicated above and below, respectively.

Fig. 3 is a diagram showing an expected structure of the hh00149 protein. In this figure, the diamond-shaped mark represents a hydrophobic region, and oval-shaped mark a hydrophilic region, respectively.

10

Best Mode for Carrying out the Invention

The present invention is described below in more detail with reference to examples, but is not construed as being limited thereto. Example 1 - Construction of library of size-fractionated human brain

15

cDNAs

cDNAs were constructed according to the method of Ohara (DNA Research 4, 53-59 (1997)). Specifically, double-stranded cDNAs were synthesized from Human poly A + RNA whole brain (CLONTECH, catalogue No. 6516-1) using the SuperScript II reverse transcriptase (GibcoBRL, catalogue No. 18064-014) with a (dT)15 primer having the Not I site at the 5' terminal end (GACTAGTTCT AGATCGCGAG CGGCCGCCCT TTTTTTTTTT TTTT/SEQ ID NO: 3) according to the manual. cDNAs thus obtained were digested with the restriction enzyme Not I, and then ligated to the Sal I adaptors. Sal I adaptors used are shown in Table 1.

25

Table 1

5'-TCGACCCACGCGTCCG-3'	(SEQ ID NO: 4)
3'-GGGTGCGCAGGC _p -5'	(SEQ ID NO: 5)

30

cDNAs shorter than 3 kb were removed by electrophoresis on 1% low-melting point agarose gel, and cDNA fragments larger than 3 kb in size were ligated to the pBluescript II SK+ (STRATAGENE, catalogue No. 212205) which had been digested with Not I and Sal I, and then transferred into ElectroMax DH10BTM cells (GibcoBRL, catalogue No: 18290-015) by electroporation according to the manual. Plasmid DNAs

were extracted from the independent 8×10^6 colonies obtained as the ampicillin-resistant colonies on agar plates by the standard alkali/SDS cytolysis method. A majority of plasmid DNAs thus obtained are the closed circular DNAs, so that their sizes fractionated by electrophoresis reflect the sizes of inserted cDNAs. Therefore, plasmid DNAs which were separated into 10 fractions on 1% agarose gel correspond to fractions separated by the size of cDNAs. Each of these fractions was separately transferred again into *E. coli*, and plasmids were extracted from 1×10^6 colonies or more per each fraction. In this case, the transformed *E. coli* was cultured on shaking in LB medium containing 100 $\mu\text{g/ml}$ ampicillin for 3 hr. Plasmids thus extracted were confirmed of their sizes by electrophoresis, and the size selection was repeated at least twice for plasmids of 8 kb or less in size, and three times for the cDNA inserts of 8 kb or more in size to construct libraries of cDNAs fractionated by size.

Example 2 - Cloning of hh00149 gene

Plasmid DNA was extracted from the above-described library of fractionated cDNAs, and sequenced. Plasmid DNA was extracted using the PI-100 automatic plasmid DNA extraction apparatus (Kurabo). The dye-primer cycle sequencing reaction was automatically performed by the CATALYST Turbo (Perkin-Elmer) using the ABI PRISM™ cycle-sequencing kit (Perkin-Elmer). Reaction products were electrophoresed using either ABI373A or ABI377 DNA sequencer, analyzed by the ABI sequence analysis system, INHERIT. cDNA inserts were sequenced from both terminals using the Dye-labeled M13 forward primer (Perkin-Elmer) and reverse primer (Perkin-Elmer). Furthermore, the entire base sequence of cDNA was determined using the shotgun method. The hh00149 gene was sequenced as one of the clones. The base sequence and putative amino acid sequence of hh00149 are shown in SEQ ID NOs: 1 and 2, respectively.

Example 3 - Chromosome mapping

The locus of hh00149 gene was mapped on chromosomes using the Gene Bridge 4 Radiation Hybrid Panel (Research Genetics, Inc.). The 10x KOD dash buffer (2 μl), 2.5 mM dNTP (1.6 μl), 10 μM primer 149-2867 (CAGGGTGGGA GAAGGGGAAA GAATC/SEQ ID NO: 6) (0.8 μl), 10 μM primer

149-2944 (GAGGCCATTG ACAGGGAGAC GAAAC/SEQ ID NO: 7) (0.8 μ l), sterilized water (13.4 μ l) and KOD dash DNA polymerase (TOYOBO #LDP-101) (0.4 μ l) were mixed, warmed at 94°C for 5 min, and then subjected to the polymerase chain reaction (PCR) of 40 repeated
5 cycles of 98°C for 10 sec, 60°C for 2 sec and 74°C for 10 sec to amplify the gene. The results were analyzed using the analysis software downloaded from the World Wide Web (<http://www.sph.umich.edu/group/statgen/software>). As a result, the hh00149 gene was mapped 3.2 cR from the landmark WI-4142 on
10 chromosome 6.

Example 4 - Tissue specificity of hh00149 gene expression by Northern blot analysis

Northern blot analysis was performed according to the usual method, using the MTN Blot (CLONTECH, catalogue Nos.: 7760-1, 7766-1, 15 7756-1, 7757-1, 7755-1 and 7769-1) with an Nco I fragment (corresponding to bases 948 to 1574 in SEQ ID NO: 1) (25 ng) which had been labeled with [α -³²P]dCTP using the Megaprime DNA labelling kit (Amersham, catalogue No. RPN1607) to serve as a probe. Prehybridization was carried out in the ExpressHyb Hybridization
20 Solution (CLONTECH, catalogue No. 8015-2) (20 ml) at 68°C for 30 min, and then hybridization was performed with the above-described labeled probe (2×10^7 cpm) similarly in the ExpressHyb Hybridization Solution (20 ml) (1×10^6 cpm/ml) at 68°C for 1 hr. The filter was washed three times at room temperature for 10 min each using 2x SSC
25 (0.3 M NaCl and 0.03 M sodium citrate (pH 7.0))/0.05% SDS) followed by further washing twice in 0.1x SSC/0.1% SDS at 50°C for 15 min. Then a FUJI Imaging plate (Fuji film) was exposed to the filter overnight, and analyzed using the FUJI BAS2000 (Fuji Film). As a result, a transcription product of 3.2 kb was specifically detected
30 in the brain, and found to be strongly expressed, as the result of analysis using the Human Brain MTN Blot II (catalogue No.: 7755-1) and Human Brain MTN Blot IV (catalogue No.: 7769-1), in the cerebral cortex, occipital lobe, frontal lobe and temporal lobe, and also to be expressed in the cerebellum, putamen and cerebellar tonsil.
35 Besides the brain, its expression was confirmed also in the spleen, testis and lung cancer A549 cells (Fig. 1).

Example 5 - RT-PCR analysis of tissue specificity of hh00149 gene expression

The expression amount of mRNA in 32 different tissues including those which had been analyzed by Northern blot was compared by RT-PCR to analyze the tissue specificity of the hh00149 gene expression. cDNAs used were the Human MTC Panel I (K1402-1), Human MTC Panel II (K1421-1), Human Fetal MTC Panel I (K1425-1) and Human Tumor MTC Panel I (K1422-1) commercially available from CLONTECH. The 10x KOD dash buffer (2 μ l), 2.5 mM dNTP (1.6 μ l), 10 μ M primer 149-2867 (CAGGGTGGGA GAAGGGGAAA GAATC/SEQ ID NO: 6) (0.8 μ l), 10 μ M primer 149-2944 (GAGGCCATTG ACAGGGAGAC GAAAC/SEQ ID NO: 7) (0.8 μ l), sterilized water (13.4 μ l) and KOD dash DNA polymerase (TOYOBO #LDP-101) (0.4 μ l) were mixed, warmed at 94°C for 5 min, and then subjected to the polymerase chain reaction (PCR) of 30 repeated cycles of 98°C for 10 sec, 60°C for 2 sec and 74°C for 10 sec. The results are shown in Fig. 2. Considerable high level of the gene expression was detected in the adult and fetal brains. The gene expression was also detected in the testis, spleen and ovary, but in no other tissues.

Example 6 - Prediction of hh00149 protein structure

The structure of the hh00149 protein was predicted using "peptide structure" and "pepplot" of the GCG Sequence Analysis Software Package (Genetic Computer Group, Oxford Molecular Group, Inc.) (Fig. 3). As a result, the amino acid sequence at the amino terminal (amino acids 1 to 20) and that (amino acids 527 to 557) are abundant in hydrophobicity, the former of which is thought to function as the signal sequence, and the latter as the transmembrane region.

Industrial Applicability

Since the membrane protein of this invention is indicated to function as a signal transducer molecule from outside to inside the cell in the brain, the membrane protein and the gene thereof are expected to be used for screening novel signal transducing substances, including neuropeptides. The membrane protein of this invention and gene thereof are expected to be applied in the development of novel remedies and diagnostics for nerve-related disorders.

CLAIMS

1. A DNA selected from the group consisting of the following (a) through (e):
 - (a) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2;
 - (b) a DNA comprising the coding region of the base sequence set forth in SEQ ID NO: 1;
 - (c) a DNA encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 2 which is modified by deletion and/or addition of one or more amino acid residues, and/or substitution with other amino acids, and functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID NO: 2;
 - (d) a DNA hybridizing to the DNA comprising the base sequence set forth in SEQ ID NO: 1, and encoding a protein functionally equivalent to the protein comprising the amino acid sequence set forth in SEQ ID NO: 2; and
 - (e) a DNA comprising a DNA according to any of (a) through (d) and a DNA encoding other peptide or polypeptide, encoding a fusion protein.
2. A vector having the DNA according to claim 1 inserted therein.
3. A transformant carrying the DNA according to claim 1 or the vector according to claim 2.
4. A protein encoded by the DNA according to claim 1.
5. A method for producing the protein according to claim 4, said method comprising the steps of culturing the transformant according to claim 3 and recovering the expressed protein from said transformant or the culture supernatant thereof.
6. An antibody binding to the protein according to claim 4.
7. A method of screening for a compound which binds to the protein according to claim 4, said method comprising the steps of:
 - (a) bringing the protein according to claim 4 into contact with a sample to be tested, and
 - (b) selecting a compound having the activity to bind to the protein according to claim 4.
8. A method for detecting or measuring the protein according to claim 4, said method comprising bringing the antibody according to

claim 6 into contact with a test sample that apparently contains the protein according to claim 4, and detecting or measuring the formation of an immune complex of said antibody and said protein.

- 5 9. A polynucleotide hybridizing to the DNA comprising the base sequence according to SEQ ID NO: 1 or a complementary strand thereof and having a chain length of at least 15 bases.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

SEQUENCE LISTING

<110> Funahashi, Shin-ichi
 Miyata, Shoji
 Nomura, Nobuo
 Nagase, Takahiro
 Ohara, Osamu

<120> NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN

<130> 06501-081001

<140> 09/831,846

<141> 2001-05-15

<150> PCT/JP99/06449

<151> 1999-11-18

<150> JP 10/331727

<151> 1998-11-20

<160> 7

<210> 1

<211> 3144

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (466)..(2832)

<400> 1

```

gcttggtcc ctctcgctga gacacacata cactcacaca tacacaaccc ggcaggctcg      60
tctgaacttg aagacacccc acattccaag atgcccagagg ttcttgggaa tgctgggggt      120
tcttcgatcc ggaaaatcct accggcatcc tcctagggag ggattattat tattatTTTT      180
ctttaatctg gaagagaaga gaacaagttg tgcttttccc cccttcttct tgctaaacgc      240
catggatata actgaataag cggctcaggg ctttccccgc gtggacgtcc gaggccacca      300
tctgctgca ttcgccggag cgcgccggag gtttagctcg agtctgtctc gggcggggaa      360
ggatgcgtgg ccgagccggg gagcccgggc gccccgcgga gccggcctcg gtgccaccca      420
gccgggggta gatgctgcct cgcccagggc ctgagtgacc agacc atg gag acc ctg      477
                                     Met Glu Thr Leu

```

1

```

ctt ggt ggc ctg cta gcg ttt ggc atg gcg ttt gcc gtg gtc gac gcc      525
Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala Val Val Asp Ala
   5                10                15                20

```

```

tgc ccc aag tac tgt gtc tgc cag aat ctg tct gag tca ctg ggg acc      573
Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu Ser Leu Gly Thr
                25                30                35

```

```

ctg tgc ccc tcc aag ggg ctg ctc ttt gta ccc cct gat att gac cgg      621
Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro Asp Ile Asp Arg
                40                45                50

```

cgg aca gtg gag ctg cgc ctg ggc ggc aac ttc atc atc cac atc agc Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile Ile His Ile Ser 55 60 65	669
cgc cag gac ttt gcc aac atg acg ggg ctg gtg gac ctg acc ctg tcc Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp Leu Thr Leu Ser 70 75 80	717
agg aac acc atc agc cac atc cag ccc ttt tcc ttt ctg gac ctc gag Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe Leu Asp Leu Glu 85 90 95 100	765
agc ctc cgc tcc ctg cat ctt gac agc aat cgg ctg cca agc ctt ggg Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu Pro Ser Leu Gly 105 110 115	813
gag gac acc ctc cgg ggc ctg gtc aac ctg cag cac ctt atc gtg aac Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His Leu Ile Val Asn 120 125 130	861
aac aac cag ctg ggc ggc atc gca gat gag gct ttt gag gac ttc ctg Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe Glu Asp Phe Leu 135 140 145	909
ctg aca ttg gag gat ctg gac ctc tcc tac aac aac ctc cat ggc ctg Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu His Gly Leu 150 155 160	957
ccg tgg gac tcc gtg cga cgc atg gtc aac ctc cac cag ctg agc ctg Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His Gln Leu Ser Leu 165 170 175 180	1005
gac cac aac ctg ctg gat cac atc gcc gag ggc acc ttt gca gac ctg Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr Phe Ala Asp Leu 185 190 195	1053
cag aaa ctg gcc cgc ctg gat ctc acc tcc aat cgg ctg cag aag ctg Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg Leu Gln Lys Leu 200 205 210	1101
ccc cct gat ccc atc ttt gcc cgc tcc cag gct tcg gct ttg aca gcc Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser Ala Leu Thr Ala 215 220 225	1149
aca ccc ttt gcc cca ccc ttg tcc ttt agt ttt ggg ggt aac cca ctt Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly Gly Asn Pro Leu 230 235 240	1197
cac tgc aat tgt gag ctt ctc tgg ctg cgg agg ctc gag cgg gac gat His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Glu Arg Asp Asp 245 250 255 260	1245
gac ctg gaa acc tgt ggc tcc cca ggg ggc ctc aag ggt cgc tac ttc Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys Gly Arg Tyr Phe 265 270 275	1293
tgg cat gtg cgt gag gag gag ttt gtg tgc gag ccg cct ctc atc acc	1341

Trp	His	Val	Arg	Glu	Glu	Glu	Phe	Val	Cys	Glu	Pro	Pro	Leu	Ile	Thr		
			280					285					290				
cag	cac	aca	cac	aag	ttg	ctg	gtt	ctg	gag	ggc	cag	gcg	gcc	aca	ctc		1389
Gln	His	Thr	His	Lys	Leu	Leu	Val	Leu	Glu	Gly	Gln	Ala	Ala	Thr	Leu		
		295					300					305					
aag	tgc	aaa	gcc	att	ggg	gac	ccc	agc	ccc	ctt	atc	cac	tgg	gta	gcc		1437
Lys	Cys	Lys	Ala	Ile	Gly	Asp	Pro	Ser	Pro	Leu	Ile	His	Trp	Val	Ala		
	310				315					320							
ccc	gat	gac	cgc	ctg	gta	ggg	aac	tcc	tca	agg	acc	gct	gtc	tat	gac		1485
Pro	Asp	Asp	Arg	Leu	Val	Gly	Asn	Ser	Ser	Arg	Thr	Ala	Val	Tyr	Asp		
325				330						335					340		
aat	ggc	acc	ctg	gac	atc	ttc	atc	acc	aca	tct	cag	gac	agt	ggg	gcc		1533
Asn	Gly	Thr	Leu	Asp	Ile	Phe	Ile	Thr	Thr	Ser	Gln	Asp	Ser	Gly	Ala		
			345					350						355			
ttc	acc	tgc	att	gct	gcc	aat	gct	gcc	gga	gag	gcc	acg	gcc	atg	gtg		1581
Phe	Thr	Cys	Ile	Ala	Ala	Asn	Ala	Ala	Gly	Glu	Ala	Thr	Ala	Met	Val		
			360				365						370				
gag	gtc	tcc	atc	gtc	cag	ctg	cca	cac	ctc	agc	aac	agc	acc	agc	cgc		1629
Glu	Val	Ser	Ile	Val	Gln	Leu	Pro	His	Leu	Ser	Asn	Ser	Thr	Ser	Arg		
		375				380						385					
act	gca	ccc	ccc	aag	tcc	cgc	ctc	tca	gac	atc	act	ggc	tcc	agc	aag		1677
Thr	Ala	Pro	Pro	Lys	Ser	Arg	Leu	Ser	Asp	Ile	Thr	Gly	Ser	Ser	Lys		
	390			395						400							
acc	agc	cgg	gga	ggt	gga	ggc	agt	ggg	ggc	gga	gag	cct	ccc	aaa	agc		1725
Thr	Ser	Arg	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Glu	Pro	Pro	Lys	Ser		
405				410					415					420			
ccc	ccg	gaa	cgg	gct	gtg	ctt	gtg	tct	gaa	gtg	acc	acc	acc	tcg	gcc		1773
Pro	Pro	Glu	Arg	Ala	Val	Leu	Val	Ser	Glu	Val	Thr	Thr	Thr	Ser	Ala		
			425					430						435			
ctg	gtc	aag	tgg	tct	gtc	agc	aag	tca	gca	ccc	cgg	gtg	aag	atg	tac		1821
Leu	Val	Lys	Trp	Ser	Val	Ser	Lys	Ser	Ala	Pro	Arg	Val	Lys	Met	Tyr		
		440					445						450				
cag	ctg	cag	tac	aac	tgc	tct	gac	gat	gag	gta	ctg	att	tac	agg	atg		1869
Gln	Leu	Gln	Tyr	Asn	Cys	Ser	Asp	Asp	Glu	Val	Leu	Ile	Tyr	Arg	Met		
		455					460					465					
atc	cca	gcc	tcc	aac	aag	gcc	ttc	gtg	gtc	aac	aac	ctg	gtg	tca	ggg		1917
Ile	Pro	Ala	Ser	Asn	Lys	Ala	Phe	Val	Val	Asn	Asn	Leu	Val	Ser	Gly		
	470					475					480						
act	ggc	tac	gac	ttg	tgt	gtg	ctg	gcc	atg	tgg	gat	gac	aca	gcc	acg		1965
Thr	Gly	Tyr	Asp	Leu	Cys	Val	Leu	Ala	Met	Trp	Asp	Asp	Thr	Ala	Thr		
485				490						495					500		
aca	ctc	acg	gcc	acc	aac	atc	gtg	ggc	tgc	gcc	cag	ttc	ttc	acc	aag		2013
Thr	Leu	Thr	Ala	Thr	Asn	Ile	Val	Gly	Cys	Ala	Gln	Phe	Phe	Thr	Lys		

505					510					515						
gct	gac	tac	ccg	cag	tgc	cag	tcc	atg	cac	agc	cag	att	ctg	ggc	ggc	2061
Ala	Asp	Tyr	Pro	Gln	Cys	Gln	Ser	Met	His	Ser	Gln	Ile	Leu	Gly	Gly	
			520					525					530			
acc	atg	atc	ctg	gtc	atc	ggg	ggc	atc	atc	gtg	gcc	acg	ctg	ctg	gtc	2109
Thr	Met	Ile	Leu	Val	Ile	Gly	Gly	Ile	Ile	Val	Ala	Thr	Leu	Leu	Val	
		535					540					545				
ttc	atc	gtc	atc	ctc	atg	gtg	cgc	tac	aag	gtc	tgc	aac	cac	gag	gcc	2157
Phe	Ile	Val	Ile	Leu	Met	Val	Arg	Tyr	Lys	Val	Cys	Asn	His	Glu	Ala	
	550					555					560					
ccc	agc	aag	atg	gca	gcg	gcc	gtg	agc	aat	gtg	tac	tcg	cag	acc	aac	2205
Pro	Ser	Lys	Met	Ala	Ala	Ala	Val	Ser	Asn	Val	Tyr	Ser	Gln	Thr	Asn	
565					570				575						580	
ggc	gcc	cag	cca	ccg	cct	cca	agc	agc	gca	cca	gcc	ggg	gcc	ccg	ccg	2253
Gly	Ala	Gln	Pro	Pro	Pro	Pro	Ser	Ser	Ala	Pro	Ala	Gly	Ala	Pro	Pro	
			585						590					595		
cag	ggc	ccg	ccg	aag	gtg	gtg	gtg	cgc	aac	gag	ctc	ctg	gac	ttc	acc	2301
Gln	Gly	Pro	Pro	Lys	Val	Val	Val	Arg	Asn	Glu	Leu	Leu	Asp	Phe	Thr	
			600					605					610			
gcc	agc	ctg	gcc	cgc	gcc	agt	gac	tcc	tct	tcc	tcc	agc	tcc	ctg	ggc	2349
Ala	Ser	Leu	Ala	Arg	Ala	Ser	Asp	Ser	Ser	Ser	Ser	Ser	Ser	Leu	Gly	
		615					620					625				
agt	ggg	gag	gct	gcg	ggg	ctg	gga	cgg	gcc	ccc	tgg	agg	atc	cca	ccc	2397
Ser	Gly	Glu	Ala	Ala	Gly	Leu	Gly	Arg	Ala	Pro	Trp	Arg	Ile	Pro	Pro	
	630					635					640					
tcc	gcc	ccg	cgc	ccc	aag	ccc	agc	ctt	gac	cgc	ctg	atg	ggg	gcc	ttc	2445
Ser	Ala	Pro	Arg	Pro	Lys	Pro	Ser	Leu	Asp	Arg	Leu	Met	Gly	Ala	Phe	
645					650					655					660	
gcc	tcc	ctg	gac	ctc	aag	agt	cag	aga	aag	gag	gag	ctg	ctg	gac	tcc	2493
Ala	Ser	Leu	Asp	Leu	Lys	Ser	Gln	Arg	Lys	Glu	Glu	Leu	Leu	Asp	Ser	
				665				670						675		
agg	act	cca	gcc	ggg	aga	ggg	gct	ggg	acg	tcg	gcc	cgg	ggc	cac	cac	2541
Arg	Thr	Pro	Ala	Gly	Arg	Gly	Ala	Gly	Thr	Ser	Ala	Arg	Gly	His	His	
		680					685						690			
tcg	gac	cga	gag	cca	ctg	ctg	ggg	ccc	cct	gcg	gcc	cgg	gcc	agg	agc	2589
Ser	Asp	Arg	Glu	Pro	Leu	Leu	Gly	Pro	Pro	Ala	Ala	Arg	Ala	Arg	Ser	
		695					700					705				
ctg	ctc	ccc	ttg	ccg	ttg	gag	ggc	aag	gcc	aaa	cgc	agc	cac	tcc	ttc	2637
Leu	Leu	Pro	Leu	Pro	Leu	Glu	Gly	Lys	Ala	Lys	Arg	Ser	His	Ser	Phe	
	710					715					720					
gac	atg	ggg	gac	ttt	gct	gct	gcg	gcg	gcg	gga	ggg	gtc	gtg	ccg	ggc	2685
Asp	Met	Gly	Asp	Phe	Ala	Ala	Ala	Ala	Ala	Gly	Gly	Val	Val	Pro	Gly	
725					730					735					740	

ggc tac agt cct cct cgg aag gtc tgc aac atc tgg acg aag cgc agc 2733
 Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp Thr Lys Arg Ser
 745 750 755

ctc tct gtc aac ggc atg ctc ttg ccc ttt gag gag agt gac ctg gtg 2781
 Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu Ser Asp Leu Val
 760 765 770

ggg gcc cgg ggg act ttt ggc agc tcc gaa tgg gtg atg gag agc acg 2829
 Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val Met Glu Ser Thr
 775 780 785

gtc taggtggggg tgggcatgct ccctttcctg tgcgcagggt gggagaaggg 2882
 Val

gaaagaatct cactggcaag tgtttgtgga gtttccatgg tgatgtttac atccagggac 2942
 agtttttgtct cccgtgcaat ggccctcgtgt cccccctac cccgcaacac ccacatcacc 3002
 tccccaccac cgggcccgggg tgtgctcagg gaatgtggac tcgctcaaat gccggactga 3062
 gccttgagtg tttggaaagg cgagactccg cctttctaata cacaaatgta gcctacaagc 3122
 aagcggcttt ggattgctta tg 3144

<210> 2

<211> 789

<212> PRT

<213> Homo sapiens

<400> 2

Met Glu Thr Leu Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala
 1 5 10 15
 Val Val Asp Ala Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu
 20 25 30
 Ser Leu Gly Thr Leu Cys Pro Ser Ser Gly Leu Leu Phe Val Pro Pro
 35 40 45
 Asp Ile Asp Arg Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile
 50 55 60
 Ile His Ile Ser Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp
 65 70 75 80
 Leu Thr Leu Ser Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe
 85 90 95
 Leu Asp Leu Glu Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu
 100 105 110
 Pro Ser Leu Gly Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His
 115 120 125
 Leu Ile Val Asn Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe
 130 135 140
 Glu Asp Phe Leu Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn
 145 150 155 160
 Leu His Gly Leu Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His
 165 170 175
 Gln Leu Ser Leu Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr
 180 185 190
 Phe Ala Asp Leu Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg
 195 200 205
 Leu Gln Lys Leu Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser
 210 215 220

Ala Leu Thr Ala Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly
 225 230 235 240
 Gly Asn Pro Leu His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu
 245 250 255
 Glu Arg Asp Asp Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys
 260 265 270
 Gly Arg Tyr Phe Trp His Val Arg Glu Glu Glu Phe Val Cys Glu Pro
 275 280 285
 Pro Leu Ile Thr Gln His Thr His Lys Leu Leu Val Leu Glu Gly Gln
 290 295 300
 Ala Ala Thr Leu Lys Cys Lys Ala Ile Gly Asp Pro Ser Pro Leu Ile
 305 310 315 320
 His Trp Val Ala Pro Asp Asp Arg Leu Val Gly Asn Ser Ser Arg Thr
 325 330 335
 Ala Val Tyr Asp Asn Gly Thr Leu Asp Ile Phe Ile Thr Thr Ser Gln
 340 345 350
 Asp Ser Gly Ala Phe Thr Cys Ile Ala Ala Asn Ala Ala Gly Glu Ala
 355 360 365
 Thr Ala Met Val Glu Val Ser Ile Val Gln Leu Pro His Leu Ser Asn
 370 375 380
 Ser Thr Ser Arg Thr Ala Pro Pro Lys Ser Arg Leu Ser Asp Ile Thr
 385 390 395 400
 Gly Ser Ser Lys Thr Ser Arg Gly Gly Gly Gly Ser Gly Gly Gly Glu
 405 410 415
 Pro Pro Lys Ser Pro Pro Glu Arg Ala Val Leu Val Ser Glu Val Thr
 420 425 430
 Thr Thr Ser Ala Leu Val Lys Trp Ser Val Ser Lys Ser Ala Pro Arg
 435 440 445
 Val Lys Met Tyr Gln Leu Gln Tyr Asn Cys Ser Asp Asp Glu Val Leu
 450 455 460
 Ile Tyr Arg Met Ile Pro Ala Ser Asn Lys Ala Phe Val Val Asn Asn
 465 470 475 480
 Leu Val Ser Gly Thr Gly Tyr Asp Leu Cys Val Leu Ala Met Trp Asp
 485 490 495
 Asp Thr Ala Thr Thr Leu Thr Ala Thr Asn Ile Val Gly Cys Ala Gln
 500 505 510
 Phe Phe Thr Lys Ala Asp Tyr Pro Gln Cys Gln Ser Met His Ser Gln
 515 520 525
 Ile Leu Gly Gly Thr Met Ile Leu Val Ile Gly Gly Ile Ile Val Ala
 530 535 540
 Thr Leu Leu Val Phe Ile Val Ile Leu Met Val Arg Tyr Lys Val Cys
 545 550 555 560
 Asn His Glu Ala Pro Ser Lys Met Ala Ala Ala Val Ser Asn Val Tyr
 565 570 575
 Ser Gln Thr Asn Gly Ala Gln Pro Pro Pro Pro Ser Ser Ala Pro Ala
 580 585 590
 Gly Ala Pro Pro Gln Gly Pro Pro Lys Val Val Val Arg Asn Glu Leu
 595 600 605
 Leu Asp Phe Thr Ala Ser Leu Ala Arg Ala Ser Asp Ser Ser Ser
 610 615 620
 Ser Ser Leu Gly Ser Gly Glu Ala Ala Gly Leu Gly Arg Ala Pro Trp
 625 630 635 640
 Arg Ile Pro Pro Ser Ala Pro Arg Pro Lys Pro Ser Leu Asp Arg Leu
 645 650 655
 Met Gly Ala Phe Ala Ser Leu Asp Leu Lys Ser Gln Arg Lys Glu Glu
 660 665 670
 Leu Leu Asp Ser Arg Thr Pro Ala Gly Arg Gly Ala Gly Thr Ser Ala

	675		680		685														
Arg	Gly	His	His	Ser	Asp	Arg	Glu	Pro	Leu	Leu	Gly	Pro	Pro	Ala	Ala				
	690					695					700								
Arg	Ala	Arg	Ser	Leu	Leu	Pro	Leu	Pro	Leu	Glu	Gly	Lys	Ala	Lys	Arg				
705					710					715					720				
Ser	His	Ser	Phe	Asp	Met	Gly	Asp	Phe	Ala	Ala	Ala	Ala	Ala	Gly	Gly				
				725					730						735				
Val	Val	Pro	Gly	Gly	Tyr	Ser	Pro	Pro	Arg	Lys	Val	Ser	Asn	Ile	Trp				
			740					745					750						
Thr	Lys	Arg	Ser	Leu	Ser	Val	Asn	Gly	Met	Leu	Leu	Pro	Phe	Glu	Glu				
		755					760					765							
Ser	Asp	Leu	Val	Gly	Ala	Arg	Gly	Thr	Phe	Gly	Ser	Ser	Glu	Trp	Val				
	770					775					780								
Met	Glu	Ser	Thr	Val															
785																			

<210> 3

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an artificially synthesized primer sequence.

<400> 3

gactagttct agatcgcgag cggccgcacct tttttttttt tttt

44

<210> 4

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an artificially synthesized adapter sequence.

<400> 4

tcgaccacg cgtccg

16

<210> 5

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an artificially synthesized adapter sequence.

<400> 5

cggacgcgtg gg

12


<210> 6

<211> 25

<212> DNA


<213> Artificial Sequence

Figure 1



0031016 002101

Figure 3



TELEPHONE NUMBER

SEQUENCE LISTING

<110> CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.

Kazusa DNA Research Institute

<120> Novel gene encoding brain-specific membrane protein

<130> C2-010PCT

<150> JP 1998-331727

<151> 1998-11-20

<160> 7

<210> 1

<211> 3144

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (466).. (2832)

4618 Rec'd PCT/PTO 1 5 MAY 2001

<400> 1

gcctggctcc ctctogctga gacacacata cactcacaca tacacaaccc ggcaggctcg 60

tctgaacttg aagacacccc acattccaag atgcccgagg ttcttgggaa tgcctggggt 120

tcttogatcc ggaaaatcct accggcatcc tcttagggag ggattattat tattatTTTT 180

ctttaatctg gaagagaaga gaacaagttg tgcttttccc cccttcttct tgctaaacgc 240

catggatata actgaataag cggctcaggg ctttccccgc gtggacgtcc gaggccacca 300

tctgectgca ttgcocggag ccgccggagg gtttagctcg agtctgtctc gggcggggaa 360

ggatgcgtgg ccgagccggg gagcccgggc gcccgcgga gccggcctcg gtgccacca 420

gccgggggta gatgctgcct cgcccaggcg ctgagtgacc agacc atg gag acc ctg 477

Met Glu Thr Leu

1

ctt ggt ggc ctg cta gcg ttt ggc atg gcg ttt gcc gtg gtc gac gcc 525

Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala Val Val Asp Ala

5

10

15

20

tgc ccc aag tac tgt gtc tgc cag aat ctg tct gag tca ctg ggg acc 573

Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu Ser Leu Gly Thr

25

30

35

ctg tgc ccc tcc aag ggg ctg ctc ttt gta ccc cct gat att gac cgg	621
Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro Asp Ile Asp Arg	
40 45 50	
cgg aca gtg gag ctg cgc ctg ggc ggc aac ttc atc atc cac atc agc	669
Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile Ile His Ile Ser	
55 60 65	
cgc cag gac ttt gcc aac atg acg ggg ctg gtg gac ctg acc ctg tcc	717
Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp Leu Thr Leu Ser	
70 75 80	
agg aac acc atc agc cac atc cag ccc ttt tcc ttt ctg gac ctc gag	765
Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe Leu Asp Leu Glu	
85 90 95 100	
agc ctc cgc tcc ctg cat ctt gac agc aat cgg ctg cca agc ctt ggg	813
Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu Pro Ser Leu Gly	
105 110 115	
gag gac acc ctc cgg ggc ctg gtc aac ctg cag cac ctt atc gtg aac	861
Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His Leu Ile Val Asn	
120 125 130	
aac aac cag ctg ggc ggc atc gca gat gag gct ttt gag gac ttc ctg	909

Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe Glu Asp Phe Leu	
135	140
145	
ctg aca ttg gag gat ctg gac ctc tcc tac aac aac ctc cat ggc ctg	957
Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu His Gly Leu	
150	155
160	
cgg tgg gac tcc gtg cga cgc atg gtc aac ctc cac cag ctg agc ctg	1005
Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His Gln Leu Ser Leu	
165	170
175	180
gac cac aac ctg ctg gat cac atc gcc gag ggc acc ttt gca gac ctg	1053
Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr Phe Ala Asp Leu	
185	190
195	
cag aaa ctg gcc cgc ctg gat ctc acc tcc aat cgg ctg cag aag ctg	1101
Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg Leu Gln Lys Leu	
200	205
210	
ccc cct gat ccc atc ttt gcc cgc tcc cag gct tcg gct ttg aca gcc	1149
Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser Ala Leu Thr Ala	
215	220
225	
aca ccc ttt gcc cca ccc ttg tcc ttt agt ttt ggg ggt aac cca ctt	1197
Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly Gly Asn Pro Leu	
230	235
240	

cac tgc aat tgt gag ctt ctc tgg ctg cgg agg ctc gag cgg gac gat 1245
 His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Glu Arg Asp Asp
 245 250 255 260

gac ctg gaa acc tgt ggc tcc cca ggg ggc ctc aag ggt cgc tac ttc 1293
 Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys Gly Arg Tyr Phe
 265 270 275

tgg cat gtg cgt gag gag gag ttt gtg tgc gag ccg cct ctc atc acc 1341
 Trp His Val Arg Glu Glu Glu Phe Val Cys Glu Pro Pro Leu Ile Thr
 280 285 290

cag cac aca cac aag ttg ctg gtt ctg gag ggc cag gcg gcc aca ctc 1389
 Gln His Thr His Lys Leu Leu Val Leu Glu Gly Gln Ala Ala Thr Leu
 295 300 305

aag tgc aaa gcc att ggg gac ccc agc ccc ctt atc cac tgg gta gcc 1437
 Lys Cys Lys Ala Ile Gly Asp Pro Ser Pro Leu Ile His Trp Val Ala
 310 315 320

ccc gat gac cgc ctg gta ggg aac tcc tca agg acc gct gtc tat gac 1485
 Pro Asp Asp Arg Leu Val Gly Asn Ser Ser Arg Thr Ala Val Tyr Asp
 325 330 335 340

aat ggc acc ctg gac atc ttc atc acc aca tct cag gac agt ggt gcc 1533

Asn Gly Thr Leu Asp Ile Phe Ile Thr Thr Ser Gln Asp Ser Gly Ala	
345	350
355	
ttc acc tgc att gct gcc aat gct gcc gga gag gcc acg gcc atg gtg	1581
Phe Thr Cys Ile Ala Ala Asn Ala Ala Gly Glu Ala Thr Ala Met Val	
360	365
370	
gag gtc tcc atc gtc cag ctg cca cac ctc agc aac agc acc agc cgc	1629
Glu Val Ser Ile Val Gln Leu Pro His Leu Ser Asn Ser Thr Ser Arg	
375	380
385	
act gca ccc ccc aag tcc cgc ctc tca gac atc act ggc tcc agc aag	1677
Thr Ala Pro Pro Lys Ser Arg Leu Ser Asp Ile Thr Gly Ser Ser Lys	
390	395
400	
acc agc cgg gga ggt gga ggc agt ggg ggc gga gag cct ccc aaa agc	1725
Thr Ser Arg Gly Gly Gly Gly Ser Gly Gly Gly Glu Pro Pro Lys Ser	
405	410
415	420
ccc ccg gaa cgg gct gtg ctt gtg tct gaa gtg acc acc acc tcg gcc	1773
Pro Pro Glu Arg Ala Val Leu Val Ser Glu Val Thr Thr Thr Ser Ala	
425	430
435	
ctg gtc aag tgg tct gtc agc aag tca gca ccc cgg gtg aag atg tac	1821
Leu Val Lys Trp Ser Val Ser Lys Ser Ala Pro Arg Val Lys Met Tyr	
440	445
450	

cag ctg cag tac aac tgc tct gac gat gag gta ctg att tac agg atg	1869
Gln Leu Gln Tyr Asn Cys Ser Asp Asp Glu Val Leu Ile Tyr Arg Met	
455 460 465	
atc cca gcc tcc aac aag gcc ttc gtg gtc aac aac ctg gtg tca ggg	1917
Ile Pro Ala Ser Asn Lys Ala Phe Val Val Asn Asn Leu Val Ser Gly	
470 475 480	
act ggc tac gac ttg tgt gtg ctg gcc atg tgg gat gac aca gcc acg	1965
Thr Gly Tyr Asp Leu Cys Val Leu Ala Met Trp Asp Asp Thr Ala Thr	
485 490 495 500	
aca ctc acg gcc acc aac atc gtg ggc tgc gcc cag ttc ttc acc aag	2013
Thr Leu Thr Ala Thr Asn Ile Val Gly Cys Ala Gln Phe Phe Thr Lys	
505 510 515	
gct gac tac ccg cag tgc cag tcc atg cac agc cag att ctg ggc ggc	2061
Ala Asp Tyr Pro Gln Cys Gln Ser Met His Ser Gln Ile Leu Gly Gly	
520 525 530	
acc atg atc ctg gtc atc ggg ggc atc atc gtg gcc acg ctg ctg gtc	2109
Thr Met Ile Leu Val Ile Gly Gly Ile Ile Val Ala Thr Leu Leu Val	
535 540 545	
ttc atc gtc atc ctc atg gtg cgc tac aag gtc tgc aac cac gag gcc	2157

Phe Ile Val Ile Leu Met Val Arg Tyr Lys Val Cys Asn His Glu Ala
 550 555 560

ccc agc aag atg gca gcg gcc gtg agc aat gtg tac tcg cag acc aac 2205
 Pro Ser Lys Met Ala Ala Ala Val Ser Asn Val Tyr Ser Gln Thr Asn
 565 570 575 580

ggc gcc cag cca ccg cct cca agc agc gca cca gcc ggg gcc ccg ccg 2253
 Gly Ala Gln Pro Pro Pro Pro Ser Ser Ala Pro Ala Gly Ala Pro Pro
 585 590 595

cag ggc ccg ccg aag gtg gtg gtg cgc aac gag ctc ctg gac ttc acc 2301
 Gln Gly Pro Pro Lys Val Val Val Arg Asn Glu Leu Leu Asp Phe Thr
 600 605 610

gcc agc ctg gcc cgc gcc agt gac tcc tct tcc tcc agc tcc ctg ggc 2349
 Ala Ser Leu Ala Arg Ala Ser Asp Ser Ser Ser Ser Ser Ser Leu Gly
 615 620 625

agt ggg gag gct gcg ggg ctg gga cgg gcc ccc tgg agg atc cca ccc 2397
 Ser Gly Glu Ala Ala Gly Leu Gly Arg Ala Pro Trp Arg Ile Pro Pro
 630 635 640

tcc gcc ccg cgc ccc aag ccc agc ctt gac cgc ctg atg ggg gcc ttc 2445
 Ser Ala Pro Arg Pro Lys Pro Ser Leu Asp Arg Leu Met Gly Ala Phe
 645 650 655 660

gcc tcc ctg gac ctc aag agt cag aga aag gag gag ctg ctg gac tcc 2493
 Ala Ser Leu Asp Leu Lys Ser Gln Arg Lys Glu Glu Leu Leu Asp Ser
 665 670 675

agg act cca gcc ggg aga ggg gct ggg acg tcg gcc cgg ggc cac cac 2541
 Arg Thr Pro Ala Gly Arg Gly Ala Gly Thr Ser Ala Arg Gly His His
 680 685 690

tcg gac cga gag cca ctg ctg ggg ccc cct gcg gcc cgg gcc agg agc 2589
 Ser Asp Arg Glu Pro Leu Leu Gly Pro Pro Ala Ala Arg Ala Arg Ser
 695 700 705

ctg ctc ccc ttg ccg ttg gag ggc aag gcc aaa cgc agc cac tcc ttc 2637
 Leu Leu Pro Leu Pro Leu Glu Gly Lys Ala Lys Arg Ser His Ser Phe
 710 715 720

gac atg ggg gac ttt gct gct gcg gcg gcg gga ggg gtc gtg ccg ggc 2685
 Asp Met Gly Asp Phe Ala Ala Ala Ala Ala Gly Gly Val Val Pro Gly
 725 730 735 740

ggc tac agt cct cct cgg aag gtc tcg aac atc tgg acg aag cgc agc 2733
 Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp Thr Lys Arg Ser
 745 750 755

ctc tct gtc aac ggc atg ctc ttg ccc ttt gag gag agt gac ctg gtg 2781

Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu Ser Asp Leu Val

760

765

770

ggg gcc cgg ggg act ttt ggc agc tcc gaa tgg gtg atg gag agc acg 2829

Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val Met Glu Ser Thr

775

780

785

gtc taggtggggg tgggcatgct ccctttcctg tgcgcagggt gggagaaggg 2882

Val

gaaagaatct cactggcaag tgtttgtgga gtttccatgg tgatgtttac atccaggac 2942

agtttcgtct ccctgtcaat ggctcgtgt cccccctac cccgcaacac ccacatcacc 3002

tccccaccac cgggccgggg tgtgctcagg gaatgtggac tcgctcaaat gccggactga 3062

gccctgagtg tttggaaagg cgagactccg cctttctaata cacaaatgta gcctacaagc 3122

aagcggcttt ggattgctta tg 3144

<210> 2

<211> 789

<212> PRT

<213> Homo sapiens

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

<400> 2

Met Glu Thr Leu

1

Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala Val Val Asp Ala

5 10 15 20

Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu Ser Leu Gly Thr

25 30 35

Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro Asp Ile Asp Arg

40 45 50

Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile Ile His Ile Ser

55 60 65

Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp Leu Thr Leu Ser

70 75 80

Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe Leu Asp Leu Glu

85 90 95 100

Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu Pro Ser Leu Gly

105 110 115

0100171820001

Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His Leu Ile Val Asn

120 125 130

Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe Glu Asp Phe Leu

135 140 145

Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu His Gly Leu

150 155 160

Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His Gln Leu Ser Leu

165 170 175 180

Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr Phe Ala Asp Leu

185 190 195

Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg Leu Gln Lys Leu

200 205 210

Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser Ala Leu Thr Ala

215 220 225

Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly Gly Asn Pro Leu

230 235 240

His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Glu Arg Asp Asp

245 250 255 260

Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys Gly Arg Tyr Phe
 265 270 275

Trp His Val Arg Glu Glu Glu Phe Val Cys Glu Pro Pro Leu Ile Thr
 280 285 290

Gln His Thr His Lys Leu Leu Val Leu Glu Gly Gln Ala Ala Thr Leu
 295 300 305

Lys Cys Lys Ala Ile Gly Asp Pro Ser Pro Leu Ile His Trp Val Ala
 310 315 320

Pro Asp Asp Arg Leu Val Gly Asn Ser Ser Arg Thr Ala Val Tyr Asp
 325 330 335 340

Asn Gly Thr Leu Asp Ile Phe Ile Thr Thr Ser Gln Asp Ser Gly Ala
 345 350 355

Phe Thr Cys Ile Ala Ala Asn Ala Ala Gly Glu Ala Thr Ala Met Val
 360 365 370

Glu Val Ser Ile Val Gln Leu Pro His Leu Ser Asn Ser Thr Ser Arg
 375 380 385

Thr Ala Pro Pro Lys Ser Arg Leu Ser Asp Ile Thr Gly Ser Ser Lys

390

395

400

Thr Ser Arg Gly Gly Gly Gly Ser Gly Gly Gly Glu Pro Pro Lys Ser

405

410

415

420

Pro Pro Glu Arg Ala Val Leu Val Ser Glu Val Thr Thr Thr Ser Ala

425

430

435

Leu Val Lys Trp Ser Val Ser Lys Ser Ala Pro Arg Val Lys Met Tyr

440

445

450

Gln Leu Gln Tyr Asn Cys Ser Asp Asp Glu Val Leu Ile Tyr Arg Met

455

460

465

Ile Pro Ala Ser Asn Lys Ala Phe Val Val Asn Asn Leu Val Ser Gly

470

475

480

Thr Gly Tyr Asp Leu Cys Val Leu Ala Met Trp Asp Asp Thr Ala Thr

485

490

495

500

Thr Leu Thr Ala Thr Asn Ile Val Gly Cys Ala Gln Phe Phe Thr Lys

505

510

515

Ala Asp Tyr Pro Gln Cys Gln Ser Met His Ser Gln Ile Leu Gly Gly

520

525

530

Thr Met Ile Leu Val Ile Gly Gly Ile Ile Val Ala Thr Leu Leu Val
 535 540 545

Phe Ile Val Ile Leu Met Val Arg Tyr Lys Val Cys Asn His Glu Ala
 550 555 560

Pro Ser Lys Met Ala Ala Ala Val Ser Asn Val Tyr Ser Gln Thr Asn
 565 570 575 580

Gly Ala Gln Pro Pro Pro Pro Ser Ser Ala Pro Ala Gly Ala Pro Pro
 585 590 595

Gln Gly Pro Pro Lys Val Val Val Arg Asn Glu Leu Leu Asp Phe Thr
 600 605 610

Ala Ser Leu Ala Arg Ala Ser Asp Ser Ser Ser Ser Ser Ser Leu Gly
 615 620 625

Ser Gly Glu Ala Ala Gly Leu Gly Arg Ala Pro Trp Arg Ile Pro Pro
 630 635 640

Ser Ala Pro Arg Pro Lys Pro Ser Leu Asp Arg Leu Met Gly Ala Phe
 645 650 655 660

Ala Ser Leu Asp Leu Lys Ser Gln Arg Lys Glu Glu Leu Leu Asp Ser
 665 670 675

Arg Thr Pro Ala Gly Arg Gly Ala Gly Thr Ser Ala Arg Gly His His

680

685

690

Ser Asp Arg Glu Pro Leu Leu Gly Pro Pro Ala Ala Arg Ala Arg Ser

695

700

705

Leu Leu Pro Leu Pro Leu Glu Gly Lys Ala Lys Arg Ser His Ser Phe

710

715

720

Asp Met Gly Asp Phe Ala Ala Ala Ala Ala Gly Gly Val Val Pro Gly

725

730

735

740

Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp Thr Lys Arg Ser

745

750

755

Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu Ser Asp Leu Val

760

765

770

Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val Met Glu Ser Thr

775

780

785

Val

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an
artificially synthesized primer sequence.

<400> 3

gactagttct agatcgcgag cggccgcct ttttttttt tttt

44

<210> 4

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an
artificially synthesized adapter sequence.

<400> 4

tcgacccacg cgtccg

16

<210> 5

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an
artificially synthesized adapter sequence.

<400> 5

cggacgcgtg gg

12

<210> 6

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an
artificially synthesized primer sequence.

<400> 6

cagggtggga gaaggggaaa gaatc

25

<210> 7

<211> 25

<212> DNA

<213> Artificial Sequence

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted February 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

<220>

<223> Description of Artificial Sequence: an
artificially synthesized primer sequence.

<400> 7

gaggccattg acagggagac gaaac

25

gaggccattg acagggagac gaaac

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL GENE ENCODING BRAIN-SPECIFIC MEMBRANE PROTEIN, the specification of which:

- is attached hereto.
- was filed on May 15, 2001 as Application Serial No. 09/831,846 and was amended on _____.
- was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
PCT	PCT/IP99/06449	November 18, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Japan	10/331727	November 20, 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

- | | | |
|--|---|-----|
| Janis K. Fraser, Ph.D., J.D., Reg. No. <u>34,819</u> | John W. Freeman, Reg. No. <u>29,066</u> | (6) |
| J. Peter Fasse, Reg. No. <u>32,983</u> | Timothy A. French, Reg. No. <u>30,175</u> | |
| Anita L. Meiklejohn, Reg. No. <u>35,283</u> | Ralph A. Mittelberger, Reg. No. <u>33,195</u> | |

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON, P.C.
225 Franklin Street
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Combined Declaration and Power of Attorney

Page 3 of 3 Pages

5-00

Full Name of Inventor: OSAMU OHARA

Inventor's Signature: Osamu Ohara Date: August 6, 2001

Residence Address: Chiba, Japan
Citizenship: Japan

Post Office Address: c/o KAZUSA DNA RESEARCH INSTITUTE
1532-3, Yana, Kisarazu-shi
Chiba 292-0812 JAPAN

20271076.doc

20010806 10:00:00

